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Abstract
Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone released by enteroendocrine 
cells lining the intestine in response to the presence of nutrients. GLP-1 is known to 
cause increased secretion of insulin from the pancreas and has been identified as one 
of the crucial components of insulin and in turn glucose homeostasis. GLP-1 has a 
very short half life of 1-2 minutes, being rapidly degraded by a ubiquitous enzyme 
called dipeptidyl dipeptidase IV and also undergoing renal excretion. Interestingly 
GLP-1 mRNA transcripts have been identified in several organs outside of the 
expected enteropancreatic axis including the heart. Insulin has been shown to reduce 
cell death in the ischemic-reperfused rat myocardium and in isolated rat myocytes via 
its ability to activate prosurvival kinase signalling pathways. We propose that GLP-1 
could protect the myocardium against ischaemia-reperfiision injury by activating 
similar prosurvival signalling pathways.
Both in-vivo (open chest) and in-vitro (Langendorff perfused) rat heart models of 
regional ischaemia and reperfusion were used. In-vivo treatment with GLP-1 
produced a significant reduction in infarction (% infarct/risk zone) compared to valine 
pyrrolidide (VP), (an inhibitor of the enzyme dipeptidyl peptidase), and control 
groups (20.0 ± 2.8, vs. 47.3 ± 4.3, and 44.3 ± 2.4, respectively PO.OOl).
In isolated perfused hearts (where there is no circulating insulin) GLP-1 significantly 
reduced infarct size compared to VP and control (26.7 ± 2.7 vs. 52.6 ± 4.7 and 58.7 ± 
4.1, PO.OOl) groups respectively. Protection was abolished in the presence of the 
PI3kinase inhibitor, LY294002 (58.6 ± 4.1), the ERK 1/2 MAPK inhibitor, U0126 
(48.3 ± 8.6), the p70s6K inhibitor, Rapamycin (57.1 ± 4.9%) and by the GLP-1 
receptor antagonist exendin-9-39 (57.3 ± 3.8). GLP-1 protects the myocardium 
against ischaemic - reperfusion injury when given throughout ischaemia - reperfusion 
or when given just five minutes prior to the onset of reperfusion or as a 
preconditioning mimetic.
To further elucidate the mechanism of GLP-1 mediated myocardial preservation we 
carried out Western blot studies examining the phosphorylation of components of the 
RISK pathway which showed an increase in the phosphorylation of BAD. The
increased phosphorylation of the pro-death peptide BAD, confirmed the potential anti- 
apoptotic effect of GLP-1.
In conclusion we have demonstrated for the first time that GLP-1 protects the rat 
myocardium against ischaemia-reperfiision injury, both in vivo and in vitro. GLP-1 
appears to protect via the up regulation of specific prosurvival kinase pathways. This 
may represent a new therapeutic potential for this class of drugs currently undergoing 
trials in the treatment of non-insulin dependent diabetes.
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Chapter 1 Introduction
1.1 Coronary Artery Disease
Coronary Artery Disease (CAD) is the largest killer in the western world and will, in 
the future, become the leading cause of mortality worldwide. CAD is caused by the 
build up of atheromatous plaques in the lining of the coronary arteries, known as 
atherosclerosis, causing limitation of coronary blood flow to the myocardium and 
hence tissue oxygen deprivation or ischaemia. Myocardial ischaemia can clinically 
present, acutely as a Myocardial Infarction (MI) or with a spectrum of disease ranging 
from chronic stable angina to heart failure. The disease may be silent or may lead to 
symptoms such as angina. In the UK, data from the British Heart Foundation (BHF) 
indicate that CAD is the most common cause of mortality. It accounts for more than 
125 000 deaths per year. Mortality rates vary by gender and account for one in four 
deaths in men and one in six in women. Morbidity is also considerable. Statistics 
indicate that approximately 1.5 million people suffer from angina and 246 000 
patients present every year with an acute myocardial infarction in the UK. Thankfully 
the majority of these are non fatal at presentation. A large percentage of patients 
require revascularisation whether performed percutaneously, surgically or with 
thrombolysis to improve their prognostic outcome. Revascularisation implies the 
restoration of coronary artery blood flow by reperfusion and hence tissue 
oxygenation. This can be achieved by the use of thrombolytic agents such as 
Streptokinase, percutaneously through procedures such as angioplasty and intra­
coronary stent placement or by surgical means by construction of Coronary Artery 
Bypass Grafts (CABG).
Myocardial ischaemia can lead to myocardial infarction and cell death with resultant 
morbidity and mortality. To salvage the myocardium from acute ischaemia, 
reperfusion is mandatory. Reperfusion brings with it life giving tissue oxygenation but 
also harbours, like a Trojan horse, deleterious consequences which have been 
collectively termed as ischaemic-reperfusion injury.
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Therefore, in order to realise an improvement in the mortality and morbidity of this 
disease, it is necessary to discover novel treatment strategies which provide protection 
to the myocardium from ischaemia-reperfiision injury.
1.2 Coronary Artery Disease and Diabetes Mellitus
Diabetes Mellitus, whether insulin dependent (IDDM or type l) or non insulin 
dependent (NIDDM or type 2) is, recognised as, a significant risk factor for the 
development of CAD (Kannel et al. 1979) A large proportion of diabetic patients 
suffer from myocardial ischaemia and its consequences. Diabetics have more severe, 
more aggressive, more complex and more diffuse coronary artery disease than do age 
matched controls. In general, coronary disease develops at a younger age than in the 
non diabetic patient. In insulin dependent diabetes, premature coronary artery disease 
is detectable in population studies from the fourth decade and by age of 55 years up to 
one third of patients have died from the complications of CAD (Fuller et al. 1983). 
The relative risk for fatal coronary heart disease associated with diabetes is 50% 
higher in women than in men (Huxley et al. 2006).
The risk of developing CAD in the patient with non insulin dependent diabetes is two 
to four times higher than the general population and does not appear to relate to either 
the severity or the duration of the diabetes, possibly because the presence of insulin 
resistance may predate the onset of clinical symptoms by 15-25 years.
Diabetes although an independent risk factor for CAD, is also associated with the 
presence of abnormalities of lipid metabolism, obesity, systemic hypertension and an 
increase in thrombogenesis (increased platelet adhesiveness and elevated levels of 
fibrinogen). Late results of coronary artery bypass grafting are less favourable in 
diabetics (Cho et al. 2006), and diabetics have both an increased early mortality and 
higher risk of re-stenosis following angioplasty.
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1.3 Preconditioning
One of the most powerful mechanisms for protecting the myocardium before the acute 
coronary artery occlusion occurs, is to ischaemically precondition the myocardium. 
Ischaemic Preconditioning (IPC) is a phenomenon which was first described in the 
seminal study by Murry and colleagues in 1986. IPC is protection against lethal 
prolonged ischaemia afforded by repeated short bursts of sub-lethal ischaemia with 
intervening reperfusion. This manoeuvre renders the myocardium more resistant to 
the ensuing lethal ischaemic period, by inducing an innate cellular adaptation 
response to stress. This, approach, however depends crucially on intervening before 
the ischaemic event, which is difficult, given the unpredictable timing of an acute 
coronary artery occlusion.
Several years after the description of acute cardiac protection by IPC, a second 
window or delayed cardioprotective effect was described (Marber et al. 1993). The 
first window of cardioprotection develops within minutes of IPC and lasts 1 -3 hours, 
whereas the second window opens 12- 24 hours after the first phase has subsided and 
lasts for 3-4 days (Bolli. 2000).
IPC has shown to protect every animal species to date, including rat, rabbit, dog, pig 
and more importantly in human myocardium during CABG (Jenkins et al. 1997, 
Yellon and Downey 2003).
Since IPC unambiguously limits infarct size in animal models a huge amount of 
research has been directed into understanding the mechanisms involved. The goal of 
this research has been not only to contribute to the understanding of the IPC 
mechanisms, but also ultimately to investigate a pharmacological agent which can be 
clinically useful in mimicking IPC and producing a protected state as well as having a 
hypoglycaemic effect.
Preconditioning Signalling
IPC has been shown to be receptor mediated (Liu et al. 1991). These receptors are 
trans-membrane G-protein coupled receptors (GPCR). A huge number of surface 
receptors capable of inducing IPC, or contributing have been confirmed. The 
multitude of GPCR are linked to a smaller number of secondary messengers such as
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Protein Kinase C (PKC) and end effectors such as the mitochondrial K-ATP channel, 
whilst other signal cascades implicated in IPC such as the Mitogen Activated Protein 
kinases (MAPKs) may lead to the modification of gene expression and be more 
important for delayed cardioprotection.
The PI3K-Akt Kinase Cascade
Recent studies have implicated signalling through the pro-survival, phosphatidyl 
inositol 3-OH kinase (PI3K)-Akt cascade, during the preconditioning phase before the 
index ischaemic episode, in IPC-induced protection. Tong and colleagues (Tong et al 
2000) were the first to demonstrate that IPC activates the PI3K-Akt kinase cascades 
prior to the index ischaemic episode, and they showed that inhibiting Akt activity, 
using the PI3K inhibitor, wortmannin, abolished IPC-induced protection, using the 
recovery of function as the end-point. Yellon’s group confirmed these findings in the 
isolated perfused rat heart infarct model. Interestingly, an earlier study (Baines et 
al.1999) had demonstrated that insulin-induced preconditioning also required the 
activation of the PI3K-Akt kinase cascade prior to the index ischaemic episode.
The PI3K-Akt signalling cascade has been implicated as a trigger of preconditioning 
(Krieg et al. 2003), such that it relays the preconditioning signal from the GPCR at the 
cell membrane to the mitochondrial K -ATP channel, where the opening of the latter 
mediates the mitochondrial release of Reactive Oxygen Species (ROS). The 
intracellular signalling pathway through which the activation of the PI3K-Akt kinase 
cascade results in the opening of the mitochondrial K-ATP channel is not clear 
although nitric oxide has been implicated. (Oldenburg et al. 2004).
Mitogen-Activated Protein Kinases (MAPKs)
The MAPKs comprise 4 major kinase cascades: the p38-MAPKs, the c-Jun N- 
terminal kinases (JNKs), the 42 and 44-kDa extracellular signal-regulated kinases 1/2 
(Erk 1/2) MAPK, and big MAPK kinase 1 (BMK1 also known as Erk5). These 4 
major kinase pathways exhibit the same conserved three-tier module in which a series 
of three protein kinases phosphorylate and activate one another (Johnson et al. 2002).
- 2 0 -
These kinase cascades are activated in response to stress such as ischaemia- 
reperfiision and receptor protein tyrosine kinases, GPCR’s and PKC.
Erkl/2 MAP Kinase
Whether the Erkl/2 MAPKs contribute to cardio-protection associated with classical 
preconditioning is unclear, with studies demonstrating that they are activated prior to 
the index ischaemic period (Mocanu et al. 2002) but not all of them show these 
MAPK’s contributing to IPC-induced protection (Strohm et al. 2000) .A recent study 
suggests that diazoxide-induced mitochondrial ROS release may activate Erkl/2 
(Samavati et al. 2002). Erkl/2 can mediate cellular protection by phosphorylating 
recruiting several anti-apoptotic mechanisms. Erkl/2 can phosphorylate and activate 
the ribosomal kinase p90RSKs which in turn can phosphorylate and inactivate the 
pro-apoptotic factor, BAD. (Harada et al. 2001)
The Reperfusion Injury Salvage Kinase Pathway: The RISK-Pathway
Yellon’s laboratory (Yellon and Baxter 1999) formulated and tested the hypothesis 
that the pharmacological activation of the signalling kinase pathways, 
phosphatidylinositol-3-OH kinase (PI3K)-Akt, and extra-cellular signal-regulated 
kinases (Erk 1/2), at the time of reperfusion protects the myocardium against lethal 
reperfusion injury. Activation of these kinase cascades (which have been termed the 
Reperfusion Injury Salvage Kinase Pathway [The RISK-Pathway] (Hausenloy et al 
.2004) protects the heart by recruiting several anti-apoptotic pathways of cellular 
survival (Figure 1.1 ).
Jonassen and colleagues (Jonassen et al. 2000a) demonstrated using an in vivo rat 
heart model of ischaemia-reperfusion injury, a reduction in infarct size associated 
with the administration of glucose-insulin-potassium (GIK) at the time of reperfusion. 
In studies using rat cardiomyocytes subjected to hypoxia, Yellon’s laboratory 
(Jonassen et al. 2000b) demonstrated that insulin given, at the time of reoxygenation, 
attenuated the apoptotic and necrotic components of cell death. In order to determine 
the mechanism of insulin-induced protection at the time of reperfusion, Yellon’s
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group (Jonassen et al. 2001) demonstrated using the isolated perfused rat heart, that 
administering insulin at the time of reperfusion activated the PI3K-Akt-BAD 
pathway, and that inhibitors of this pathway such as wortmannin (the PI3K inhibitor), 
and rapamycin (the mTOR inhibitor), abrogated insulin-induced protection. 
Administering insulin at the time of reperfusion activated this kinase cascade. The 
early perfusion of insulin was essential for protection, as delaying its administration to 
15 minutes after the onset of reperfusion, was not associated with protection, 
suggesting that the protection via the PI3-Akt kinase cascade was mediated in the first 
few minutes of reperfusion. (Jonassen et al. 2001) In an in vivo rat heart model of 
ischaemia-reperfusion injury, eNOS, another downstream target of Akt 
phosphorylation, has been implicated (Gao et al. 2002), in insulin-mediated cardio- 
protection at reperfusion.
The activation of the pro-survival PI3K-Akt and MEK 1/2-Erk 1/2 cascades at the 
time of reperfusion, by ligands to growth factor or G-protein coupled receptors, 
protects the heart against lethal reperfusion injury. The protective mechanisms 
induced by these kinase cascades are mediated by the diverse array of substrates 
which these kinases phosphorylate.
The PI3K-Akt kinase signalling cascade is activated in response to the 
activation of a wide range of receptors, including those for growth factors and G- 
protein coupled receptors (Cross et al. 2000). In response to ligand-receptor binding, 
the p85 regulatory subunit of PI3K is phosphorylated, which results in the activation 
of the pi 10 catalytic subunit of PI3K, which in turn phosphorylates the membrane 
lipid, phosphatidylinositol 4,5 biphosphate (Franke et al. 1997) to 
phosphatidylinositol 3,4,5-triphosphate, which then recruits Akt (also known as PKB) 
to the membrane. Upstream kinases such as 3-phosphoinositide-dependent protein 
kinases 1 and 2 (PDK1 and 2) then phosphorylate and activate Akt at Thr-308 and 
Ser-473. (Datta et al. 1996).
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Figure 1.1 : Scheme Outlining Proposed Pathways leading to cell 
Survival.
Protecting the Heart Against Lethal Reperfusion Injury: 
Targeting Akt and Erk1/2, the (RISK)-Pathway
Ligand-Receptor Binding
PI3K Raf-1RAS
MEK1/2
BIMCaspase 9 MDM.eN O S
BAX Gene
Expressionp90S 6Kp53
BAD
mPTP|
Protein
Translationp70S 6K NucleusMitochondria
Cytochrome C 
Release INHIBITED
Legend: Agents which protect bind to receptors, which via the small G-protein, RAS, activate the 
PI3K-Akt and R afl-M E K l/2 -E rk l/2  kinase cascades, which together comprise the Reperfusion Injury 
Salvage Kinase (RISK)-pathway. Protection against lethal reperfusion injury is then mediated by the: 
(1) phosphorylation and inactivation o f  pro-apoptotic factors, caspases 3 and 9, BIM, BAX, BAD and 
p53, one consequence o f which is to prevent the release o f  mitochondrial cytochrome C in response to 
an apoptotic stimulus (shown by dashed arrows); (2) phosphorylation and activation o f  eNOS 
(endothelial nitric oxide synthase), producing nitric oxide which may protect by inhibiting opening o f 
the mitochondrial permeability transition pore (mPTP); (3) phosphorylation and activation o f  p70s6K 
and p90S6K which can protect by inactivating BAD or regulating protein transcription/translation; and 
(4) regulating the expression o f genes concerned with cellular survival.
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The activation of Akt phosphorylates a diverse array of substrates, influencing 
numerous cellular processes, many of which are anti-apoptotic in action. Downstream 
targets of PI3K-Akt are shown in Figure 1.1 which mediate anti-apoptotic effects.
The evidence lends itself to the suggestion that the pro-survival kinase 
cascades may therefore constitute a common pathway, mediating the cardio- 
protection induced by IPC on the one hand, as well as protecting the myocardium 
through their recruitment at the time of reperfusion, on the other hand. However, the 
only direct evidence for this rests with insulin-induced cardio-protection, and 
therefore more research is needed to elucidate whether the pro-survival kinase 
cascades actually constitute the common pathway for cardio-protection in these two 
settings.
The significant action of insulin in cardioprotection led us to take an interest in 
insulinotropic agents such as GLP-1.
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1.4. Glucagon-like peptide-1
1.4.1 Introduction
In the early 1980s, the structure of mammalian pre-proglucagon was deduced from the 
cloned DNA, and found to contain, in addition to glucagon itself, the sequences of 
two related peptides, which were termed glucagon-like peptide (GLP) -1 and -2 
because of their considerable sequence homology to glucagon (Bell et al. 1983). Fig.
1.2 A single glucagon gene encodes a larger biosynthetic precursor, proglucagon, in 
mammals. Tissue-specific processing of proglucagon gives rise to glucagon in the 
brain, and glicentin, oxyntomodulin, GLP-1, and GLP-2 in the intestine, with an 
intermediate profile of peptides liberated in the central nervous system. GLP-1 and 
GLP-2 are produced in the same gut endocrine cells and liberated, following 
posttranslational processing of a single proglucagon precursor. The available evidence 
suggests that only one proglucagon gene is expressed in mammals that gives rise to an 
identical mRNA in brain, pancreas, and intestine (Mojov et al. 1986). The tissue- 
specific liberation of proglucagon is controlled by cell-specific expression of 
prohormone convertase (PC) enzymes. An essential role for PC2 in the processing of 
islet proglucagon is revealed by studies of the PC2 knockout mouse. This mouse has 
mild hypoglycemia, elevated proinsulin, and exhibits a major defect in the processing 
of proglucagon to mature pancreatic glucagon, and the murine islet a  cells secrete 
proglucagon from atypical secretory granules. Fig. 1.3
Thereafter a search for the biological function of these additional peptides began, but 
initial progress was slow. Based upon the presence of pairs of basic amino acids, 
typically sites at which prohormone processing occurs, a 37 amino acid peptide, GLP- 
1 (1-37) was predicted to be secreted, but this peptide turned out not to affect glucose 
or insulin concentrations significantly, even when administered in high doses 
(Ghiglione et al. 1984). It was for a further several years before two naturally 
occurring truncated forms, GLP-1 (7-36) amide (0rskov et al. 1986) and GLP-1 (7- 
37) (Mojsov et al. 1987) were identified. With the demonstration that these truncated
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forms were probably the most potent insulinotropic agents hitherto known (Holst et al. 
1987; 0rskov et al. 1988, Mojsov et al. 1987), interest in GLP-1 research grew 
explosively.
Figure 1.2 Am ino Acid sequence o f hum an glucagon precursor
Amino Acid S e q u e n c e  of Glucagon P recu rso r  (Human)
signal sequence
1 MKSIYFVAGL FVMLVQGSWQ RSLQDTEEKS RSFSASQADP 40
Gicertin-Related Polypeptide 
41 LSDPDQMNED KRRSQGTFTS DYSKYLDSRR AQDFVQWLMN 80
Glucagor______________________OXM_______
81 TKRNRNNIAK RHDEFEf|hAE GTFTSDVSSY LEGQAAKEFI 120
OXM GLP-1
121 AWLVKGRGRR DFPEEVAIVE ELGRR i^ADGS FSDEMNTILD 160  
GLP-1
161 NLAARDFIHW L1QTKITD(rK 180  
GLP-2
GLP-2
Legend
Primary accession number P01275
Structure of the human glucagon gene. White J.W., Saunders G.F.; Nucleic Acids 
Res. 14:4719-4730(1986).
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Figure 1.3 Structure o f proglucagon and biological actions o f GLP-1 and GLP-2.
Glicentin
r-Oxyntomodulin
Proglucagon Glucagon IP- GLP-1 IP-: GLP-2GRPP
Gastric 
emptying 
Acid secretion 
Food intake
GLP-2R+
Enteroendocrine
cells
Target cells Islet p cells
-CL
CNS stress response
Hypothalamic pituitary function
Insulin biosynthesis and secretion
Glucagon Secretion
Somatostatin Secretion
Islet Cell Proliferation and neogenesis
Islet Cell differentiation
-CL
Gastric Acid Secretion 
Gl motility
Intestinal permeability 
Intestinal hexose transport 
Crypt cell proliferation 
Enterocyte and crypt apoptosis 
Small and large bowel growth
The principal target cell types for GLP-1 (islet 15 cells) and G LP-2 (intestinal endocrine  
cells) are shown below the peptide sequences. G R PP, G licentin-related pancreatic  
polypeptide; IP, intervening peptide; G L P-2R , glucagon-like peptide-2 receptor. 
(D rucker et al. 2003)
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1.4.2 Pancreatic Actions
GLP-1 possesses a number of properties which make it a potentially ideal anti­
diabetic agent. It is released from the intestinal L-cell in response to orally ingested 
nutrients (Elliott et al. 1993; Herrmann et al. 1995) and has potent effects upon the 
endocrine pancreas, the gastrointestinal tract and in the brain.
In the pancreas, GLP-1 acts as an incretin hormone, stimulating meal-induced insulin 
secretion (0rskov et al. 1996a). This effect is glucose-dependent, so that the 
insulinotropic effect is potentiated at elevated blood glucose concentrations and wanes 
as normoglycaemia is approached (Weir et al. 1989), meaning that any risk of 
hypoglycaemia during exogenous peptide administration is practically eliminated. 
Not only does GLP-1 stimulate insulin exocytosis, but it also promotes all steps in 
insulin biosynthesis (Fehman & Habener 1992), while more recently, direct effects on 
beta cell have been identified. Thus, GLP-1 acts to promote beta cell growth and 
survival by stimulating both proliferation (Xu et al. 1999; Stoffers et al. 2000) and 
differentiation of new beta cells (Zhou et al. 1999; Perfetti et al. 2000), as well as by 
reducing beta cell apoptosis (Farilla et al. 2002; Li et al. 2003), resulting in increased 
beta cell mass. In addition to its effects on the beta cells, GLP-1 also influences the 
alpha cells, such that glucagon secretion is strongly inhibited (0rskov et al. 1988). 
Notably, this glucagonostatic effect also is glucose-dependent (Nauck et al. 2002), 
meaning that GLP-1 administration is unlikely to impair the glucagon counter- 
regulatory response to hypoglycaemia. In the gastrointestinal tract, GLP-1 inhibits 
motility and secretion (Wettergren et al. 1993), thereby contributing to reduce the 
glucose excursion by delaying the passage of nutrients to the small intestine. Indeed, 
under physiological circumstances in healthy subjects, delayed gastric emptying 
appears to outweigh the insulinotropic effect of GLP-1 (Nauck et al. 1997). In 
humans, peripherally administered GLP-1 has a satiating effect, not only in healthy 
normal weight subjects (Flint et al. 1998), but also in obese subjects (Naslund et al. 
1999) and in patients with type 2 diabetes (Gutzwiller et al. 1999a). Thus, when 
given over a prolonged period (6 weeks) by continuous subcutaneous infusion, 
patients with type 2 diabetes reported a reduction in appetite, which led to a 
significant reduction in body weight by the end of the study (Zander et al. 2002). Part 
of the mechanism appears to be related to a reduced gastric emptying rate (Verdich et
- 2 8 -
al. 2001), but a reduced sensation of appetite during GLP-1 in the fasting state, before 
meal ingestion (Gutzwiller et al. 1999b), suggests other mechanisms may also 
contribute. Central administration of GLP-1 inhibits food intake in rodents (Tang- 
Christensen et al. 1996; Turton et al. 1996), raising the possibility that peripherally 
released GLP-1 may have a direct effect on the brain. This is because circulating 
GLP-1 can access GLP-1 receptors in areas of the brain (subfornical organ, area 
postrema) which participate in the regulation of appetite and energy homeostasis 
(0rskov et al. 1996b). However, it is also relevant that gastric distension activates 
GLP-1 -containing neurons in the caudal nucleus of the solitary tract, suggesting a role 
for centrally expressed GLP-1 as an inhibitor of food intake (Vrang et al. 2003). 
Interestingly, central administration of the GLP-1 receptor antagonist, exendin (9-39), 
increases food intake (Turton et al. 1996; Meeran et al. 1999), suggesting that GLP-1 
produced locally within the brain may exert a tonic satiating effect.
In 1992, it was demonstrated that GLP-1 was also effective in patients with type 2 
diabetes (Gutniak et al. 1992; Nathan et al. 1992), and could normalise blood glucose 
in both the fasting and the fed state in these subjects when given as a continuous 
intravenous infusion (Nauck et al. 1993; Rachman et al. 1996; Larsen et al. 2001), 
even in those patients with advanced type 2 diabetes long after sulphonylurea 
secondary failure (Nauck et al. 1998).
However, unexpectedly, the effects of a single subcutaneous injection of GLP-1 were 
disappointing. Although high plasma levels of immunoreactive GLP-1 were achieved 
(Nauck et al. 1996), insulin secretion rapidly returned to pre-treatment values and 
blood glucose concentrations were not normalised (Nauck et al. 1996; Juntti-Berggren 
et al. 1996; Todd et al. 1997). However, the effect of repeated subcutaneous 
administration on fasting blood glucose is as good as that of intravenous 
administration (Nauck et al. 1996), while continuous subcutaneous administration for 
6 weeks reduces fasting and post-prandial glucose concentrations and lowers HbAlc 
concentrations (Zander et al. 2002).Fig 1.3 and 1.5.
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Figure 1.4 Scheme illustrating the known physiological actions of GLP-1 
Meal
v DPP IV
(t1/2 < 2min)
GLP-1 -------------------------------- ► Inactive incretins
(Antagonists)
• Improves Insulin synthesis and secretion
• Stim ulates p cell growth
• Prom otes satiety
• Delays gastric motility and secretion
• Increased glucose disposal in fat, m uscle and liver
• Improves insulin receptor binding
• D ecreases glucagon and gluconeogenesis
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1.4.3 The GLP-1 receptor
The GLP-1 receptor (GLP-1 R) is widely expressed in pancreatic islet p-cells, kidney, 
lung, the brain particularly in the hypothalamic paraventricular and arcuate nucleus, 
the gastrointestinal tract, and interestingly, also in the heart (Wei et al. 1995). The 
presence of the GLP-1 receptor in various organs suggests the possibility of an 
extended physiological role for GLP-1 outside of its primary incretin action. The 
receptor for GLP-1 is coupled to heterotrimeric Gas proteins. Thus the GLP-1 R is a 
GPCR, and is a distinct member of the glucagon-secretin receptor super family that 
has been shown to function by causing intracellular calcium influx in addition to up- 
regulating cyclic-adenosine monophosphate(c-AMP) (Holz et al. 1995). Interestingly, 
c-AMP has been demonstrated, in several cell types other than myocardial, to protect 
against apoptosis (Kwon et al. 2003 and Hui et al. 2003). Although considerable effort 
has been expended in searching for a second GLP-1 receptor, only a single receptor 
has been isolated to date.
Specific agonist and antagonists of the GLP-1 R have now been isolated as discussed 
later in section 5.1.2
1.4.4 GLP-1 metabolism
Native GLP-1 has a short half life of minutes, being rapidly degraded by dipeptidyl 
peptidase-IV (DPP-IV), to generate an N-terminally truncated metabolite. In addition, 
GLP-1 undergoes renal excretion from the circulation. Dipeptidyl peptidase-IV, (EC 
3.4.14.5), also known as the T-cell antigen CD26, is a serine exopeptidase. DPP-IV 
rapidly (Tm<2 min) cleaves off a dipeptide at the penultimate alanine near the amino 
terminus of GLP-1 (7-36) amide and generates the inactive or antagonistic GLP-1 (9- 
36) amide (Pauly et al. 1996). Therefore, in order to assess the roles of intact GLP-1, 
it is necessary to use a DPP-IV inhibitor, namely valine pyrrolidide (VP), as a means 
of preventing its degradation (Deacon et al. 1998).
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Figure 1.5 Chemical Structure of VP
CH
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1.4.5 Cardiac Effects of GLP-1
A number of different groups have looked at differing aspects of GLP-1 in the 
myocardium and cardiovascular physiology. However the role of GLP-1 in ischaemic- 
reperfusion injury has not previously been explored. Cellular studies in isolated 
cardiac myocytes have demonstrated elevated c-AMP levels as a result of exposure to 
GLP-1 as well as demonstrating chronotropic effects (Vila Petroff et al. 2001). In vivo 
studies have been performed examining the effect of GLP-1 on blood pressure and 
heart rate (Barragan et al. 1994 and Yamamoto et al. 2002). Fascinatingly, a centrally 
mediated component to the effect of GLP-1 on haemodynamic parameters has been 
clearly identified (Barragan et al. 1999 and Isbil-Buyukcoskon et al. 2004). The 
majority of the literature demonstrates a role for GLP-1 in cardiovascular physiology 
with most in vivo experiments showing elevated blood pressure and heart rate as a 
result of GLP-1 infusion (Yamamoto et al. 2002). However some studies have failed
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to demonstrate any haemodynamic effects with GLP-1 (Deacon et al. 1996). This may 
be due to species differences, the dose of GLP-1 used in the studies, and the use of 
inhibitors of the enzymatic degradation of GLP-1 such as DPPIV. Studies using 
knock-out mice have also suggested a role for the GLP-1 R in the control of cardiac 
structure and function (Gros et al. 2003). GLP-1R knock out mice were found to have 
reduced body weight and heart weight with thicker than expected ventricular walls. 
There were no overt cardiac histological differences between the wild type mice and 
knockouts.
More importantly, a recent clinical study demonstrated that GLP-1 improved left 
ventricular function in patients with acute myocardial infarction and left ventricular 
dysfunction (Nikolaidis et al. 2004). The same group have now gone on to 
demonstrate improved recovery of left ventricular function in a large animal model of 
ischaemia-reperfusion induced stunning (Nikolaidis et al. 2005).
The metabolic effects of GLP-1 in the myocardium are also of great interest as the 
insulin / glucose axis in cardioprotection has been the cornerstone of many academic 
departments. In particular, the balance between free fatty acid (FFA) oxidation and 
glucose oxidation remains crucial. Although free fatty acids are preferred as metabolic 
substrate for the heart under normal conditions, glucose becomes the preferred 
substrate during ischaemia. Initially it was thought that the provision of glucose 
benefits the myocardium by increasing glycolytic ATP and by decreasing free fatty 
acids usage. This results in a more efficient use of oxygen for the production of ATP, 
thus easing the heart’s workload. Thus, developed, the hypothesis that clinical 
infusions of glucose-insulin-potassium (GIK) would be of benefit in myocardial 
infarction or induced ischaemia as occurs during cardiopulmonary bypass procedures. 
Indeed GIK treatments have had some success in the reduction of mortality and 
morbidity (Opie 1999, Sack and Yellon 2003), albeit at the cost of hypoglycaemia, 
volume overload or hypokalaemia.
The actions of GLP-1 as an insulinotropic agent and any effects on glucose 
homeostasis could directly influence this axis.
Another potential cardiovascular action for GLP-1 has been as a vascular endothelial 
relaxant. A randomised cross over trial in human subjects tested the effect of GLP-1 
infusion on brachial artery blood flow (Nystrom et al. 2004). This study clearly
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demonstrated changes in brachial artery diameter in GLP-1 treated type 2 diabetic 
subjects compared to non diabetic control subjects suggesting an additional beneficial 
effect in endothelial dysfunction. This group also found that GLP-1 had no affect on 
insulin resistance in their study. A role in endothelial function has also been 
demonstrated in the pulmonary vasculature where receptors for GLP-1 have also been 
identified, mediated possibly through a nitric oxide dependent pathway (Golpon et al. 
2001).
The exact physiological role for GLP-1 in the myocardium has yet to be clearly 
identified. However, of specific interest is the fact that GLP-1 has been also shown to 
promote the activity of phosphoinositide 3-kinase (PI3K) in (3 cells (Buteau et al. 
1999). This kinase has been clearly associated with myocardial protection in the 
setting of ischemic-reperfusion injury (Hausenloy et al. 2004) as well as myocardial 
preconditioning’ (Tong et al. 2000 and Mocanu et al. 2002)
Recent data has suggested that GLP-1 can exert a direct cytoprotective effect via 
inhibition of apoptosis, either directly in target cells expressing the GLP-1 R, or 
possibly via the activation of survival factors (Redondo et al. 2003). GLP-1 has also 
been shown to protect against apoptosis in insulinoma cell lines through both c-AMP 
and PI3K (Hui et al. 2003). In this context, it is important to bear in mind that insulin 
has been shown to activate pro survival kinases such as PI3K (Jonassen et al. 2001), 
which have been proposed as integral components of anti-apoptotic cascades involved 
in myocardial protection.
1.5 Summary and Main Objectives of the Thesis
This thesis explores the actions of GLP-1 in the myocardium exposed to ischaemic- 
reperfusion injury. The aim of this study was to examine the direct effect of GLP-1 on 
the ischaemic myocardium in both the in vivo (insulin dependent) and in vitro (insulin 
independent) rat myocardium, assessing myocardial infarct size as an end-point of 
injury in both models. Furthermore, an additional aim was to investigate the cellular 
mechanisms underlying the protective effect of GLP-1 against myocardial ischaemia- 
reperfusion injury.
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Figure 1.6 Known actions o f  GLP-1
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Chapter 2 General Methods
2.1 Introduction
The effects of ischaemia and ischaemic-reperfusion injury have been studied in 
numerous settings including the whole organism, the isolated whole myocardium, and 
myocardial cellular preparations. Preliminary investigations to test concepts are 
commonly performed in animal models as ethical implications preclude the use of the 
human heart model in most scientific research. Fragments of knowledge put together 
from different types of experimental models create the pieces of the jigsaw for the 
design of successful potential treatment. Regional ischaemia, infarct size limitation 
and heart function in the rodent isolated perfused heart as well as in vivo are the basis 
o f the experimental approach used here.
Experiments described in this thesis have been performed in the laboratory of The 
Hatter Institute and Centre for Cardiology, University College London Hospitals and 
Medical School, London, UK. These studies were conducted in accordance with The 
Home Office Guidance on the operation of Animals (Scientific Procedures) Act, 
1986.
2.2 Choice of animal model
The rat is an established experimental species, and both the in vivo and isolated heart 
preparation has been extensively characterised. The ease of breeding and maintenance 
of these animals is favourable compared to other species. Sprague-Dawley rats were 
used in our experiments and were purchased from Charles River, Bicester, Oxon. 
Male animals were consistently used as gender has been shown to influence infarct 
size in models of ischaemic-reperfusion injury in the rat recently (Brown et al. 2005,
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Pitcher et al. 2005, Wang et al 2005). The animals were housed in groups of four to a 
cage in the animal house and were fed a standard pellet chow. They were allowed to 
acclimatise for a minimum of four days prior to use, during which time a 12 hour 
light-dark cycle was maintained at 19-22° C, and 55 ± 10% humidity.
2.3 In Vivo Procedure
The aim of the in vivo procedure was to produce a dynamic model of myocardial 
ischaemia in which the effects of pharmacological agents on the myocardium as well 
as their systemic effects could be measured. In particular as GLP-1 has been identified 
as a potent incretin hormone it was important to use a model in which its action on 
insulin levels and hence glucose homeostasis could theoretically be observed.
2.3.1 Anaesthesia
All rats used for in vivo experiments were anaesthetised with a mixture of Hypnovel 
(midazolam 5 mg/ml, Roche, Welwyn Garden City, UK) and Hypnorm (0.315 mg/ml 
fentanyl and 10 mg/ml fluanisone, Jansen Animal Health, High Wycombe, UK). This 
mixture was made by adding 1ml of Hypnovel with 2ml sterile water for injection 
followed by 1ml of Hypnorm and giving 0.27ml per lOOg bodyweight (Flecknell
1996) together with heparin (llU/g) given by intra-peritoneal (i-p) injection. 
Consciousness was usually lost within 5 minutes and no longer than 10 minutes after 
injection. The animal was then weighed and transferred to the operating area. 
Adequate depth of anaesthesia was confirmed by the loss of the pedal withdrawal 
reflex before thoracotomy was performed.
Further doses of anaesthesia were given intra-venously (iv) at 20 minute intervals or 
earlier as required for maintenance of anaesthesia.
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2.3.2 Surgical Procedure
A longitudinal midline incision was made in the neck to expose the strap muscles. The 
trachea was identified and exposed to allow a tracheosotomy to be performed. An 
endotracheal tube placed under direct vision to allow ventilation and secured in 
position with silk ties. The endotracheal tube was connected to a small animal 
ventilator from Harvard Apparatus, (Edenbridge, UK) and ventilated with oxygen at a 
rate of 70-80 breaths per minute and a tidal volume of 1.0 to 1.5 mis. Next the right or 
left external jugular vein was dissected and isolated. Central venous access to the 
jugular vein was gained and a line inserted, allowing infusions to be set up. Further 
doses of anaesthesia were given intra-venously (iv.) at 20 minute intervals or earlier 
as required for maintenance of anaesthesia. To allow transduction of blood pressure 
and heart rate, the left carotid artery was isolated and cannulated. The arterial line was 
connected to a pressure transducer (Oxnard, CA), and readings taken through a pen 
chart recorder-Multitrace2 (Lectromed, Letchworth, UK) to give continuous blood 
pressure (BP) and Heart rate (HR) / pulse measurement. Intermittent arterial blood gas 
analysis with a blood gas analyser ABL-705 was performed (Radiometer Medical 
Instruments, Copenhagen, Denmark). Ventilation was adjusted (rate or tidal volume) 
to maintain a physiological pH (7.35-7.45), pC02 and p02.
A left parasternal thoracotomy was performed to gain access to the heart. The 
pericardium was fully opened. The left anterior coronary artery was identified and a 
6.0 suture was placed carefully around it, near its origin, from the left main coronary 
artery. The suture was then used to thread a plastic snare to permit reversible 
occlusion of the coronary artery. The animal was then allowed to stabilise for 15 to 20 
minutes. To induce ischaemia, the snare was tightened around the coronary artery. 
Ischaemia was confirmed by regional ischaemic pallor, hypokinesia and a fall in BP. 
ECG recordings were taken to confirm the presence of myocardial ischaemia. The 
snare was relaxed at the end of the 30 minute ischaemic time period to allow 
reperfusion of the myocardium for 120 minutes.
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2.3.3 Exclusion Criteria
Procedural exclusion criteria included blood loss of more than approximately 1 ml 
during the operative procedure, a mean arterial pressure < 90 mmHg during 
stabilisation, poor temperature control with rectal temperature under or above 36-37.5 
°C, excessive bleeding from the epicardial surface on tightening of the snare and 
induction of ischaemia, and metabolic acidemia with a pH < 7.35. Animals with a 
weight range between 300-450g were used for in vivo experiments.
2.3.4 Parameters measured
1) Electrocardiogram
This was recorded using a three lead ECG capture system (ADI Instruments, 
Oxfordshire, UK).
2) Blood pressure and Heart rate
After placement of an intra-arterial cannula, this is connected to a pressure transducer 
and then onto the pen chart recorder (Lectromed, Letchworth, UK).
3) Ventilator rate and tidal volume
The small animal ventilator used allows the rate and tidal volume to be adjusted and 
hence recorded (Harvard Apparatus, Edenbridge, UK).
4) Arterial blood gases and Blood glucose
The arterial cannula allows blood samples to be taken and analysed for blood gases 
and glucose using the blood gas analyser described.
5) Insulin levels
To measure insulin levels, serum was separated from fresh blood samples and frozen 
at -20°C. Samples were packed in dry ice and couriered to be batch processed in at 
NovoNordisk, Bagsvaerd, Denmark.
Preparation of drugs 
GLP-1
GLP-1 in an anhydrous crystalline form was kept frozen at -20°until required. The 
GLP-1 was then dissolved in pure water to form a solution of 5 pmol and infused at 
the rate of 4.8 pmolkg'1min'1.
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Valine pyrrolidide
VP obtained from Novo Nordisk was kept as a powder at room temperature. The 
appropriate amount was weighed out depending on the weight of the animal to give a 
dose of 20 mg kg'1 and dissolved in 0.5 ml of normal saline and given by 
subcutaneous injection 30 minutes prior to the commencement of the experiment.
2.4 Isolated heart studies
2.4.1 The Langendorff heart preparation
2.4.1.1 Principle
The underlying principle is to force blood, or any other oxygenated fluid appropriate 
to maintain cardiac activity, towards the heart through a cannula inserted into the 
ascending aorta in a technique described by Oscar Langendorff (1853-1908). 
Retrograde perfusion closes the aortic valve -  just as in the in situ heart during 
diastole -  and the perfusate is displaced through the coronary arteries into the 
coronary sinus and opened right atrium. The cardiac cavities remain basically empty 
throughout the experiment and do not perform pressure -volume work.
The Langendorff preparation is appropriate for all warm blooded animals with a 
coronary vascular system. Human hearts have been kept alive for several hours during 
heart surgery using this principle. The preparation can be operated with either a 
constant flow or constant pressure. From a physiological standpoint, perfusion at 
constant pressure should be given preference, because whenever possible mean 
perfusion is maintained constant in the in intact circulation (Sutherland et al. 2000).
2.4.1.2 Measuring parameters
Mechanical parameters of the working myocardium (contractile force, volume and 
ventricular diameter), mean coronary flow, bioelectrical parameters
- 4 0 -
(electrocardiogram, monophasic injury potentials) and cardiac rhythm can be 
measured and recorded (Sutherland et al. 2000).
The intact function of the working myocardium and coronary vessels can be examined 
using various simple tests regarding the myocardium, the smooth musculature and the 
endothelium of the coronary vessel. Due to technical ease, a variety of parameters can 
be measured, providing information on the state of the myocardium and coronary 
vessels. Further these experiments can be easily repeated and are economically 
feasible. The heart tends to remain devoid of central neuronal stimulation / 
depression, which makes it ideal for studying the direct effects of treatments.
2.4.2 Chemicals and drugs
Chemicals used for Krebs-Henseleit buffer [containing in (mmol/1) 118 NaCl, 25 
NaHC03l 11 glucose, 4.7 KC1, 1.2 MgS04. 7H20, 1.2 KH 2 P 04, and 1.8 Ca Cl 2 .2H 
20], were purchased from BDH Laboratory Supplies (Merck Eurolab, UK). Carbogen 
(95% 0 2 / 5% C 02) to aerate and maintain the buffer pH was obtained from our local 
hospital supplies. GLP-1 and Valine Pyrrolidide were supplied by Novo Nordisk, 
Bagsvaerd, Denmark. Rapamycin, U0126 and LY294002 were obtained from Tocris, 
UK. Exendin 9-39 from Bachem, UK and Rp-cAMP from Calbiochem, UK. 
Triphenyl-tetrazolium chloride (TTC) and formaldehyde were purchased from Sigma 
(Poole, UK).
2.4.3 Perfusion equipment
The Langendorff apparatus used in these studies were based on the same principle as 
originally pioneered by Oscar Langendorff in 1895. A schematic representation of the 
apparatus and the actual apparatus Powerlab ML 176 (ADI Instruments, Oxfordshire, 
UK) used in these experiments are shown in figure 2.1 and 2.2 respectively. The 
buffer was maintained at a pH 7.3-7.5 and was monitored using a blood gas analyser 
(ABL-705, Radiometer Medical Instruments, Copenhagen, Denmark). Left ventricular 
pressures were transduced through a saline filled latex balloon.
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Figure 2.1
Schematic representation of the apparatus
perfusion 
pressure 
transducer
heart chamber
95%C^+5%C02
reservoir---------
perfusion fluid
sintered glass 
gas distributor
T e m p e r a t u r e
pro be perfusion cannula with side arm
transducer
balloon 
coronary effluent
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Figure 2.2 Actual apparatus used for in vitro experiments
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2.4.4 Anaesthesia
All animals used for in vitro experiments were anaesthetised with sodium 
phenobaritone (Sagatal 50 mg/kg) obtained from Rhone Merieux, Dublin, Eire. This 
was administered intra-peritonealy (ip) and concomitantly with heparin (1 IU/g) 
obtained from Leo Laboratories Ltd (Bucks, UK) to prophylactically prevent 
thrombosis in the coronary vasculature or ventricular chambers. Consciousness was 
usually lost within 5 minutes and no longer than 10 minutes after injection. The 
animal was then weighed and transferred to the operating area. Adequate depth of 
anaesthesia was confirmed by the loss of the pedal withdrawal reflex before 
thoracotomy was performed.
2.4.5 Isolated heart preparation
To optimise the field of view a subcoastal incision was performed to gain access to 
the xiphisternal process, from whence the thorax was opened to expose the 
mediastinum and its contents. The heart is excised quickly by transecting the great 
vessels superiorly and the inferior vena cava inferiorly and immediately transferred to 
ice cold buffer solution to arrest contraction. The heart was then mounted onto the 
Langendorff apparatus by carefully holding the aorta with forceps and introducing the 
perfusion cannula into the aortic lumen. With practice this procedure can be 
completed safely without damaging the aortic valve or coronary ostia and without 
preconditioning the heart by exposing it to a prolonged ischaemic insult (Minhaz et al. 
1995; Awan et al. 1999). Perfusion should ideally be restored as quickly as possible 
and is achievable in 1-2 minutes. Buffer flow was adjusted automatically by the 
perfusion apparatus to maintain a constant perfusion pressure which was fixed at a 
constant 75 mmHg. A saline filled latex balloon connected to a pressure transducer 
was inserted into the left ventricle (LV), and baseline end-diastolic pressure was set at 
5-10 mmHg. Heart rate, LV end-diastolic pressure and developed pressure were 
recorded continuously. A 3.0 suture was placed around the left main coronary artery 
and threaded through a plastic snare to permit reversible occlusion of the coronary 
artery. Myocardial temperature was monitored by introducing a probe into the right 
ventricular outflow tract and maintained at 36-37°C with the aid of a thermostat
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controlled water bath around the buffer reservoirs. A heating lamp and warming 
chamber were also used in thermoregulation. A bubble trap in the system reduces the 
probability of an air embolism to heart from the perfusate.
2.4.6 Regional Ischaemia
A period of 15 minutes stabilisation was used during which the hearts were allowed to 
equilibrate prior to the induction of ischaemia. Regional ischaemia, was induced, by 
tightening a plastic snare on the suture around the left anterior descending coronary 
artery. Figure 2.3 and 2.4 Coronary occlusion was maintained for 35 minutes by 
clamping the snare onto the heart. Ischaemia was confirmed by regional ischaemic 
pallor, hypokinesia and a fall in rate pressure product and coronary flow. Reperfusion 
was achieved by releasing the snare which was often accompanied by reperfusion 
arrhythmias and a gradual improvement in rate pressure product and coronary flows. 
When regional ischaemia has been employed it becomes necessary to delineate the 
field of the occluded artery. This field is referred to the region at risk or the risk zone, 
as it is at risk of infarction. At the end of 120 minutes reperfusion, the left main 
coronary artery was re-ligated using the 3.0 suture already placed and the risk zone 
delineated with Evans Blue dye infused via the aortic root. Figure 2.5 demonstrates a 
heart with the risk zone demarcated by Evans Blue.
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Figure 2.3 In Vitro heart in stabilisation
Figure showing heart in stabilization with perfusion cannula tied in the proximal 
aorta, temperature probe in right ventricular outflow tract, pressure transducer line 
entering left atrial appendage excision site and suture placed widely around left 
anterior descending coronary artery
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Figure 2.4 In vitro heart in ischaemia
Plastic pipette tip snare pulled tight to 
Induce regional ischaemia
Figure showing snare pulled tight on suture around left anterior descending coronary 
artery to induce regional ischaemia
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Figure 2.5 Evans Blue demarcation o f area at risk
Figure showing area at risk or risk zone demarcated with Evans Blue dye after the 
suture around the left anterior coronary artery has been tied down.
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2.4.7 Parameters measured
2.4.7.1 Coronary flow  rate
The Langendorff hearts were perfused at a constant pressure, hence coronary flow 
was linked to the vascular resistance of the coronary arterial beds, as determined by 
heart contraction and arteriolar vascular smooth muscle tone. Coronary flow was 
measured by a pressure transducer built into the ADI perfusion apparatus which relays 
into the Powerlab recording software. An electronic feed-back circuit controls a 
peristaltic pump for constant-pressure perfusion of isolated hearts (Shattock et al.
1997). Coronary flow was monitored at regular intervals throughout the experiment. 
In control hearts not subjected to ischaemia coronary flow was found to diminish with 
time.
2.4.7.2 Temperature
Hypothermia has been shown to play an important role in the attenuation of 
ischaemia-reperfusion injury (Hale et al. 1997). The maintenance of a controlled 
temperature within strict limits is therefore crucial. Therefore temperatures were 
maintained carefully between 36-37° C and recorded continuously by the Powerlab 
apparatus.
2.4.7.3 Rate pressure product
The rate-pressure product (RPP) is a good and reliable index of cardiac workload and 
function. It is calculated as the product of the ventricular heart rate and developed 
pressure at a given time and is expressed as millimetres of mercury per minute 
(mmHg m in 1). Continuous recordings of the RPP were made.
- 4 9 -
2.4.8 Infarct size evaluation
At the end of the 120 minute reperfusion protocol, perfusion through the aortic 
cannula was terminated. The suture around the left coronary artery used to induce 
ischaemia, is then tied off to effectively halt any flow down the coronary artery. 
Evans Blue dye was then retrogradely infused into the aortic cannula and hence into 
the coronary arteries to delineate the risk zone as described above (section 2.4.6). 
Hearts were rapidly frozen, then sectioned (2 mm) and incubated in 1% triphenyl- 
tetrazolium chloride (TTC) in phosphate buffer (pH 7.4, 37°C) for 12 minutes to stain 
viable tissue red as opposed to the non-stained white necrotic tissue. TTC staining is a 
widely recognised, validated method of staining for myocardial infarction (Ito et al. 
1997; Schwarz et al, 2000). TTC in-fact stains non infracted viable tissue due its 
reduction by NADH and other cofactors producing a formazan pigment which is 
visible as a red stain. This is distinct from non stained white infracted tissue. Fig.2.6, 
2.7 and 2.8 The tissue was then fixed in 4% formalin for 24 hours.
The formalin fixed and stained heart slices were mounted onto a glass plate. A cover 
glass plate was then placed over the tissue. Two millimetre thick shims in the comers 
hold the glass plates away from each other. The risk area, infracted and non infracted 
areas were demarcated. Images of the sections were drawn, by a blinded operator, on 
to an acetate sheet. The risk zone areas and infarct to risk ratios were determined by 
computerized planimetry. Fig 2.8 (Planimetry + version 1.0 for Windows Boreal 
Software Inc)
- 5 0 -
Figure 2.6 Stained heart slice showing Infarction in area at risk
TTC stained heart slice showing infarction as white and live tissue as pink 
within the risk zone. The non risk area is stained blue.
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Figure 2.7
Infarcted area
atC o n tro l
b) GLP-1
Tetrazolium-Stained Heart Slices: taken from (a) control hearts) and (b) GLP-1 
treated hearts. The slices demonstrate areas o f infarction (white), non-infarcted risk 
area (red) and non-risk area (blue). Note the smaller infarct area in the GLP-1 
treated hearts vs. the control hearts.
Figure 2.8
(a) Control
Non* F-risk areaV
tiskjarea
r **
b)GLP-1 e Infarction* 4* r
Planimetry Heart Slices: taken from (a) control and (b) GLP-1 treated hearts stained 
depicting infarcted areas (red), non-infarcted risk area (green) and non-risk area 
(yellow).
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2.4.9 Perfusion protocol
2.4.9.1 In Vitro
Animals were randomly assigned to one of the followings groups: 1) Control group in 
which hearts were stabilised for 15-20 minutes and then subjected to 35 minutes of 
regional ischaemia, followed by 120 minutes of reperfusion, and 2) treatment groups, 
which received drugs added to buffer starting during stabilisation and continued 
throughout the experiment until termination of the experiment. Fig 2.9 Our initial in 
vitro treatment experiments were performed with GLP-1 at a concentration of 0.3 nM 
in combination with VP at the concentration 20mg I'1 of buffer, as an inhibitor of 
DPPIV. This was in essence to repeat the in vivo experiments in an in vitro setting to 
explore the effects of GLP-1 in isolation and in the absence of other circulating 
factors such as insulin. Further experiments were then performed as detailed in 
chapter 5 and 6 to explore the mechanism of the action of GLP-1 in myocardial 
ischaemic-reperfusion injury.
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Figure 2.9 Schematic of in vitro experimental protocols
Hearts in all groups are stabilised for a minimum of 15-20 minutes. In Group 2 and 
Group 3 treatments (VP 20mgl'1 and GLP-1 0.3 nmol) were added to the perfusate 
during stabilisation and continued throughout the experiment.
Group 1 Control
Stabilisation 15 Ischaemia 35 min Reperfusion 120 min
Group 2 VP
Stabilisation IS Ischaemia 35 min Reperfusion 120 min
VP 20mgl1
Group 3 GLP-1 +VP
Stabilisation 15 Ischaem ia 35 min Reperfusion 120 min
GLP-1 0.3nM /VP 20mgl‘
O 
C/3 
1 
H—
( 
Z 
l-H 
Z 
O
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2.5 Western blot analysis
Western blotting is useful in detecting a protein of interest that may be mixed with 
others (such as in a cell lysate) or verifying the identity of a protein on a gel. In 
general, a mixture of proteins is resolved using a denaturing acrylamide gel and then 
transferred from gel onto a nitrocellulose membrane. The proteins of interest are 
probed by incubating the membrane with specific antibodies. The membrane is next 
incubated with a secondary antibody which recognises any bound primary antibody, 
and allows eventual identification. This technique is limited by the success of the gel 
separation, the transfer step and specificity of the antibodies.
Chemicals used for Western blotting include sodium dodecyl sulphate (SDS), Trizma 
base (Tris), ammonium persulphate (APS), TEMED, bromophenol blue, Ponceau 
solution, reagents for suspension /sample buffers were purchased from Sigma (Poole, 
UK). Methanol and glycine were purchased from BDH Laboratories (Merck Eurplab, 
Dorset, UK) and Acrylamide (protogel) from National diagnostics (Hull, UK). The 
anti-BAD (rabbit polyclonal Ig G), phospho-Akt, phospho-eNOS, phospho-ERK 1/2, 
phospho-BAD (Ser 136), phospho-BAD (Ser 112) and horseradish peroxidase 
(HRP)-linked anti-rabbit Ig G (H&L) were purchased from Cell Signalling technology 
(Hertfordshire, UK). Nitrocellulose membrane and ECL plus detection reagents were 
obtained from Amersham Biosciences (Buckinghamshire, UK).
2.5.1 Tissue Preparation
All samples for Western blot analysis were collected from Langendorff perfused 
hearts rather than in vivo studies. All hearts were stabilised for a period of 15 minutes 
prior to treatment. From the literature it is apparent that GLP-1 causes a very brief 
enhancement in the phosphorylation and hence activation of anti-apoptotic factors and 
therefore a number of different time points were used for the collection of tissue 
samples in order to try and capture the point of phosphorylation as detailed in chapter
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5. Control hearts were run for the same length of time. Experiments were performed 
with and without ischaemia. Ischaemia was achieved by cessation of perfusion and 
was global rather then regional. Again careful attention was paid to temperature 
control during the preparation.
At the termination of the Langendorff period, perfusion was stopped and the heart 
freeze-clamped with a pre-cooled Wollenberger clamp in liquid nitrogen after 
excision of both atria. Samples were stored at -80° C.
2.5.2 Protein Extraction
The tissue samples were extracted in a lysis buffer containing (in mM): 0.1 NaCl, 
10 Tris (pH = 7.6), 1 EDTA, 2 Na pyrophosphate, 2 NaF, 2 p-glycerophosphate, 
0.5 AEBSF and "Sigma Cocktail" protease inhibitor mixture. They were homogenized 
at 4 °C with IKA-Ultra-Turrax homogenizer (Staufen, Germany) and sonicated twice 
for 10 seconds, then centrifuged at 14,000 rpm for 5 min at 4 °C. The purified protein 
was then further diluted in sample buffer (Tris 100-pH 6.8), DTT 200 mM, SDS 2%, 
bromophenol blue 0.2% and glycerol 20%) and subsequently boiled for 10 min at 
100° C. The supernatant was stored for protein quantification and the remainder of the 
sample for electrophoresis.
2.5.3 Protein quantification
Protein content was determined with BCA Protein Assay Reagent kit (Pierce, 
Rockford, USA). This assay is based on the formation of a purple coloured BCA- 
copper complex as a consequence of the reduction of ionised cooper, which is 
measured by optical densitometry at 562 nm.
A standard curve for known concentrations of bovine serum albumin (BSA) using 
optical density and a photospectrometer (Janway model 6405 UV/Vis, Dunmow, UK) 
was constructed. The protein in the samples were then quantified using this method,
- 5 6 -
and the protein content compared against the standard curve to provide an estimate of 
the protein concentration (pg/pl) to enable equal loading of the polyacrylamide gel.
2.5.4 Polyacrylamide gel electrophoresis
2.5.4.1 Gel preparation
12.5% acrylamide gels were made using 36ml deionised water, 16 ml acrylamide, 18 
ml running gel base ( 1.5 M Tris and 0.4% SDS in deionised water, pH 8.8) 80 pi 
TEMED and 400 pi 10 % ammonium sulphate). The running gel is poured between 
two glass plates separated by spacers and sealed with Vaseline. A stacking gel made 
with 14 ml deionised water, 6 ml stacking gel base (0.5 M Tris, 0.4 % SDS in 
deionised water, pH 6.8), 4 ml 30 % acrylamide, 40 pi 8 % bromophenol blue, 48 pi 
TEMED and 240 pi 10 % APS was then introduced above the running gel and protein 
loading wells were constructed by placement of a plastic insert.
2.5.4.2 Electrophoresis
A total of 30 pg of protein for each sample was loaded into the gel. To provide control 
banding 10 pi of a molecular weight rainbow marker and 30 pg protein from human 
endothelial cell lysate were also loaded. The gel was run for 4 hours at 125 Volts 
constant.
2.5.5 Protein Transfer
Following electrophoresis, a similar size of Hybond ECL nitrocellulose membrane 
was apposed to the gel and both were sandwiched between sheets of filter paper, 
carefully displacing any air bubbles that may have been introduced. A transfer tank 
containing transfer buffer, - 200 ml methanol, 700 ml deionised water and 100 ml lOx 
transfer buffer (glycine, Tris and deionised water). Transfer proceeded at 140 mA 
constant overnight (12-14 hours). The next morning, after removal of the membranes,
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equal protein loading was confirmed with Ponceau red staining (Sigma Chemicals 
Poole, UK) of the membranes.
2.5.6 Immunoblotting
The membranes were then washed for 15 minutes ( 3 x 5  minute cycles) with a 
washing buffer (50 ml lOx Tris-buffered saline (TBS)., 450 ml deionised water and 
0.5 ml Tween-20) To prepare 1 litre of lOx TBS:24.2g Tris base, 80g NaCl: Adjust 
pH to 7.6 with HC1. Then incubate on a rocking platform in blocking buffer (washing 
buffer and 5 % non-fat milk) for 3 hours.
2.5.7 Primary antibody
The membranes were subsequently, washed in washing buffer and one incubated in 
primary antibody in a concentration of 1:1000 for 2 hours.
2.5.8 Secondary antibody
A secondary antibody was prepared with an-anti rabbit secondary antibody (1:2500). 
Before application of the secondary antibody for 1 hour, the primary antibody was 
washed off with washing buffer. Proteins were detected by using enhanced 
chemiluminescence ECL Western blotting reagent (Amersham Biosciences, 
Amersham, UK) and bands were visualised by autoradiography onto Kodak film.
2.5.9 Quantification
Autoradiography films and Ponceau stained membranes were scanned on to a flat-bed 
picture scanner and the digital image saved to disc. Images may be calibrated against 
densitometer values if one of the lanes has been so measured. Results are expressed as
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a percentage of wild-type control expression (± SEM) and corrected for Ponceau red 
(Sigma) determined protein loading.
2.6 Statistical analysis
Statistical analysis was performed using Apple Macintosh software package StatView 
Version 4.5. Data was expressed as means ± SEM. One way analysis of variance 
between group means was performed using an ANOVA factorial method.
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Chapter 3 Glucagon Like Peptide-1 In Vivo
3.1 Introduction
The aim of this thesis was to explore the actions of GLP-1 on the myocardium and in 
particular to identify any affect that GLP-1 has on ischaemic-reperfusion injury. Our 
initial hypothesis, that GLP-1 may activate known myocardial preservation pathways 
such as the reperfusion injury salvage kinase or RISK pathway (Hausenloy et al. 
2004) was constructed around its potent action as an incretin (a substance that leads to 
increased insulin secretion or production). Insulin has previously been shown to be 
able to protect the ischaemic myocardium both experimentally (Jonassen et al. 2001) 
and in the clinical setting. (Diaz et al.1998). Insulin has also been put forward as an 
anti-inflammatory and antiatherosclerotic hormone (Dandona et al. 2003). To test the 
hypothesis that GLP-1 may protect the myocardium against ischaemic-reperfusion 
injury through its incretin action, we needed to use a whole body model of myocardial 
ischaemic reperfusion injury with an intact pancreatic insulin secreting apparatus on 
which GLP-1 could act as an incretin. The role of GLP-1 in myocardial ischaemic- 
reperfusion injury was, therefore, studied initially in the in vivo rat model. This whole 
animal model allowed us to evaluate the actions of GLP-1 on myocardial ischaemic- 
reperfusion injury with myocardial infarction as an end point but to also study the 
haemodynamic cardiovascular physiological effects of GLP-1 in a well described and 
accepted model.
The whole animal model also gave us the opportunity to measure circulating levels of 
insulin and dipeptidyl peptidase IV (DPPIV), the enzyme involved in the degradation 
of GLP-1 as well as products of GLP-1 degradation. GLP-1 as described in chapter 1, 
is cleaved from a precursor peptide sequence. The fragments of GLP-1 degradation 
may have a metabolic action such as the inactive or antagonistic GLP-1 (9-36) amide 
(Pauly et al. 1996). Therefore, the ability to measure the levels of insulin, intact GLP- 
1, DDPIV levels and GLP-1 fragments whilst determining the cardiovascular actions 
of GLP-1 in terms of ischaemic-reperfusion injury which the whole animal model 
allows had distinct advantages as an initial tool.
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A number of previous studies have looked at individual aspects of GLP-1 function in 
the cardiovascular setting. From previous isolated myocardial cell studies (Vila 
Petroff et al. 2001) GLP-1 has been shown to have actions in the cardiac setting 
causing increases in c-AMP levels. This action of GLP-1 is thought to be 
compartmentalized, with the c-AMP produced as a result of GLP-1 treatment being 
locked in particular micro domains with a consequent restriction of the c-AMPs’ 
actions. There have been some studies have shown that GLP-1 has haemodynamic 
effects, whilst others have failed to demonstrate any effects on blood pressure or heart 
rate. In addition a possible central role in the actions of GLP-1 on blood pressure and 
heart rate has also been demonstrated. These experiments were devised to try and 
characterise the actions of GLP-1 on myocardial infarction as the primary end point. 
Secondary end points included the metabolic and haemodynamic effects of GLP-1.
3.2 Materials and Methods
Male adult Sprague-Dawley rats (350-450g) were used for these studies.
3.3 Anaesthesia
For a detailed explanation of the anaesthetic protocol used see chapter two section
2.3.1
3.4 Surgical Procedure
A tracheosotomy was performed using a longitudinal midline incision. The trachea 
was identified and exposed. An endotracheal tube placed under direct vision to allow
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ventilation and secured in position with silk ties. For a detailed description see Section
2.3.2
3.5 Characterisation of the in vivo model
Initial experiments were performed to characterise and define the in vivo rat model of 
myocardial ischaemic reperfusion injury used in these studies. The in vivo model has 
been previously used and characterised extensively in the Hatter Institute, however, 
further experiments were performed to repeat the experience of previous investigators 
and to establish consistency on this investigators part using this experimental model. 
After stabilisation for approximately 20 minutes, control experiments were performed 
using initially 20 minutes of ischaemia. Further experiments were then performed 
using 25 minutes, 30 minutes and lastly 35 minutes of ischaemia to explore the effect 
of the duration of the ischaemia on the percentage of infarction in the area at risk. In 
each group the ischaemic period was followed by release of the snare around the 
coronary artery and reperfusion for two hours.
The results of these experiments are shown in figure 3.1
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Figure 3.1 Myocardial Infarction as a percentage in the area at risk with different periods of 
ischaemia
B
Legend
In vivo myocardial infarct size expressed as a percentage of the risk zone. A= 20 
minutes ischaemia, B= 25 minutes ischaemia , C= 30 minutes ischaemia, D= 35 
minutes ischaemia n=6 per group.
Results are presented as means ± SEM
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3.6 Ischaemic protocols
From the result of these experiments we found that 30 minutes of ischaemia produced 
the most reliable and reproducible degree of infarction whilst coupled with a good 
success rate in completing the reperfusion period of two hours.
3.7 Infarct size evaluation
On completion of the 120 minute reperfusion period a lethal dose of anaesthesia was 
given and the heart was rapidly harvested from the animal. The heart is quickly 
mounted onto a Langendorff apparatus with a cannula placed in the aorta and tied in 
place holding the heart. The suture around the left coronary artery used to induce 
ischaemia, is then tied off to effectively halt any flow down the coronary artery. 
Evans Blue dye was then retrogradely infused into the aortic cannula and hence into 
the coronary arteries to delineate the risk zone as described in chapter 2 (section 
2.4.8). Hearts were rapidly frozen, then sectioned (2 mm) and incubated in 1% 
triphenyl-tetrazolium chloride (TTC) in phosphate buffer (pH 7.4, 37°C) for 12 
minutes to stain viable tissue red as opposed to the non-stained white necrotic tissue. 
TTC staining is a widely recognised, validated method of staining for myocardial 
infarction (Ito et al. 1997; Schwarz et al. 2000). TTC in-fact stains non infracted 
viable tissue due its reduction by NADH and other cofactors producing a formazan 
pigment which is visible as a red stain. This is distinct from non stained white 
infracted tissue. The tissue was then fixed in 4% formalin for 24 hours.
The formalin fixed and stained heart slices were mounted onto a glass plate. A cover 
glass plate was then placed over the tissue. Two mm thick shims in the comers hold 
the glass plates away from each other. The risk area, infracted and non infracted areas 
were demarcated as shown in figure 2.7. Images of the sections were drawn by a
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blinded operator on to an acetate sheet. Fig 2.8 The risk zone areas and infarct to risk 
ratios were determined by computerized planimetry. (Planimetry + version 1.0 for 
Windows
3.8 Treatment Groups
Rats were randomly assigned to either control or treated groups. Two groups were 
used for in vivo treatment experiments. Treated animals were divided into two groups; 
those given only Valine pyrrolidide and those given both GLP-1 and Valine 
pyrrolidide. VP, at the dose of 20 mg kg'1, was administered as a subcutaneous 
injection 30 minutes prior to the commencement of anaesthesia and the subsequent in 
vivo experiment. GLP-1 was infused into the central venous line, placed during 
preparation of the model, at a dose of 4.8 pm olkg'W n'1. Fig 3.2 Blood samples were 
taken prior to the commencement of the GLP-1 infusion to estimate blood glucose, 
insulin levels, DPPIV activity and native GLP-1 levels. Further blood samples were 
taken through out the experimental protocol to measure arterial blood gases and blood 
glucose at 30 minute intervals. A terminal blood sample was taken to measure insulin, 
GLP-1 and DPPIV activity at the end of the reperfusion period.
3.8.1 Groupl Control
These animals were anaesthetised, without pre-medication, but were given a 
subcutaneous injection of 0.5 ml of normal saline, the vehicle used for dissolving VP, 
in order to standardise the procedure. After a stabilisation period of 15-20 minutes 
they were subjected to 30 minutes of regional myocardial ischaemia followed by two 
hours of reperfusion prior to termination of the experiment and estimation of the 
degree of myocardial infarction using TTC staining.
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3.8.2 Group 2 VP
This group was given a subcutaneous injection of VP thirty minutes prior to the 
commencement of anaesthesia. They were stabilised for a period of 15-20 minutes 
and then subjected to 30 minutes of regional myocardial ischaemia followed by two 
hours of reperfusion prior to termination of the experiment and estimation of the 
degree of myocardial infarction.
3.8.3 Group 3 GLP-1 and VP
Again this group were given a subcutaneous injection of VP 30 minutes prior to the 
commencement of the experiment. After a stabilisation period of 15-20 minutes, the 
infusion of GLP-1, at 4.8 pmolkg'W n'1, into the jugular vein was started and allowed 
to run for 10 minutes prior to the start of ischaemia, following which they underwent 
the same protocol as the groups mentioned above.
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Figure 3.2 Schematic of in vivo experimental protocols
Group 1 Control
Stabilisation 15 Ischaemia 30 min Reperfusion 120 min
Group 2 VP
Stabilisation 15 Ischaemia 30 min Reperfusion 120 min
VP
T
GLP-1 Infusion 4.8 pmolkg^min'1 continued throughout protocol
Group 3 GLP-1 +VP
Stabilisation 15 Ischaemia 30 min Reperfusion 120 min
Hearts in all groups were stabilised for a minimum of 15-20 minutes. Those in the 
GLP-1 group were stabilised for a further 10 minutes following commencement of the 
GLP-1 infusion.
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3.9 Statistical analysis
Statistical analysis was performed using Apple Macintosh iMac computers and the 
statistical package StatView Version 4.5. Data was expressed as means ± SEM. One 
way analysis of variance between group means was performed using an ANOVA 
factorial method. P  values of less than 0.05 were taken to show statistical 
significance.
3.10 Results
3.10.1 Technical exclusions
A total of fifty eight animals were used in the in vivo experiments. Ten animals were 
excluded for technical reasons which included a high mortality rate during the initial 
procedures. The initial high mortality was ascribed to a learning curve prior to 
obtaining technical proficiency. The most common reason for exclusion was the 
development of ventricular fibrillation during ischaemia and early reperfusion which 
led to the exclusion of 7 experiments. This was almost inevitably a terminal event 
when occurring in reperfusion. A number of experiments did not complete the 
required two hours of reperfusion due to blood loss from the epicardial surface where 
the snare had caused local trauma. The number of experiments performed to 
characterise the model was twenty four, whilst the comparative study was performed 
with a further twenty four experiments.
3.10.2 Infarct size and risk zone
There were no significant differences between the groups for body weight, cardiac 
weight and risk volume Table 3.1.The infarct to risk ratio in the control and VP
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treated groups was 44.3 ± 2.4% and 47.3 ± 4.3% respectively. GLP-1 + VP was seen 
to protect the myocardium with an infarct to risk ratio of 20.0 ± 2.8%, 
from ischaemia-reperfusion injury in the in vivo open chest rat heart model, 
demonstrating a significant reduction in infarction compared to the VP or control 
groups, P  <0.001, n=8per group respectively. Fig. 3.3
3.10.3 Heart rate and blood pressure
As expected the blood pressure in all the groups declined after the initiation of 
ischaemia. The initial reduction in blood pressure was characteristically between 30- 
50% of the stabilisation values. During the early phase of reperfusion the blood 
pressure would improve but this would be followed by a gradual reduction throughout 
ischaemia. The results for the three groups are represented in Table 3.2
Table 3.1 In vivo body weight, heart weight and risk volume
Groups Number Body Weight 
(g)
Heart Weight 
(g)
Risk volume 
(cm3)
1. Control 8 386±8 1.83±0.06 0.533±0.041
2. VP 8 400±5 1.88 ±0.02 0.568±0.038
3. GLP-1 8 390±8 1.86±0.20 0.562±0.046
Values are mean ± SEM. There was no significant statistical difference between the 
groups.
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Figure 3.3 In vivo myocardial infarction
T  50
B
In vivo myocardial infarct size expressed as a percentage of the risk zone. A= Control 
n= 8, B= Valine Pyrrolidide n=8, C=. Glucagon-like peptide-1 n=8
Results are presented as means ± SEM (* = P<0.001 vs. Control and VP)
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Table 3.2 : In vivo Mean Arterial Blood Pressure (MAP) and Heart Rate (HR)
Stabilisation 5 min 
Ischaemia
20 min 
Ischaemia
15 min 
Reperfusion
Control
MAP
HR
n=8
120 ± 4  
400 ± 8
80 ± 7 
368 ± 4
73 ± 4  
364 ± 10
76 ± 3  
364 ± 16
Valine
Pyrrolidide
MAP
HR
n=8
127 ± 4  
404 ± 8
79 ± 6 
360 ±5
77 ±5  
354 ± 9
78 ± 7  
358 ± 12
GLP-1
MAP
HR
n=8
125 ± 3  
406 ± 5
74 ± 7  
356 ± 9
78 ± 4 
362 ±12
75 ± 4 
354 ± 14
Values are means ± SEM.
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3.10.4 Glucose
Glucose readings were taken at regular intervals using an arterial blood gas analyser 
(ABL-705, Radiometer Medical Instruments, Copenhagen, Denmark).The results 
shown in Table 3.3 demonstrate that there were no statistically significant differences 
between absolute blood glucose levels in any of the groups at the two time points used 
for sampling. Statistical significance was found, however if the reduction in blood 
glucose was compared between groups over the time course of the experiment with 
the GLP-1 treated group showing the greatest reduction in glucose levels compared to 
the other two groups. This is demonstrated in figure 3.4
3.10.5 Insulin levels
Table 3.4 demonstrates the different values obtained for insulin in all the in vivo 
experiments in which the insulin assay was performed. As can be seen from the table 
there was wide variability in the insulin levels, which is discussed further in the next 
section. There were no statistically significant differences between the three groups.
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Table 3.3
In Vivo Plasma glucose levels
Blood Sugar Baseline Terminal Blood Sugar
A: control 7.100 8.200
A: control 11.400 8.900
A: control 9.200 7.400
A: control 7.600 6.300
A: control 8.000 9.100
A: control 9.900 9.300
B: Valine 9.400 10.000
B: Valine 16.200 5.800
B: Valine 10.000 8.400
B: Valine 10.300 6.900
B: Valine 9.600 6.900
B: Valine 10.500 7.400
B: Valine 10.700 7.700
B: Valine 11.300 6.900
C: GLP-1 15.600 9.300
C: GLP-1 15.800 10.100
C: GLP-1 10.700 8.800
C: GLP-1 11.800 7.900
C: GLP-1 9.300 5.400
C: GLP-1 8.000 6.800
C: GLP-1 9.900 5.000
C: GLP-1 7.400 3.700
Values are expresses as mmol/1
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Figure 3.4. In vivo reduction in blood glucose
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In vivo terminal Blood glucose reduction expressed as a percentage. A= Control «=6, 
B= Valine Pyrrolidide n=8, C=. Glucagon-like peptide-1 n=8
Results are presented as means ± SEM (* = PO .05 vs. Control and VP)
- 7 4 -
Table 3.4
In Vivo Plasma insulin levels
Baseline Insulin Terminal Insulin
A: control 234 83
A: control 416 260
A: control 223 83
A: control 315 7194
A: control 132 251
A: control 619 275
B: Valine 319 191
B: Valine 428 400
B: Valine 433 230
B: Valine 405 962
B: Valine 3743 608
C: GLP-1 412 2331
C: GLP-1 262 250
C: GLP-1 427 121
C: GLP-1 964 4999
C: GLP-1 413 576
C: GLP-1 250 263
C: GLP-1 419 209
C: GLP-1 1099 398
Values are expresses as pmol/1
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3.11 Discussion
In this part of the study we demonstrated that GLP-1 provided significant protection 
against myocardial ischaemic-reperfiision injury in an in vivo rat model compared to 
control experiments. Further we demonstrated that in isolation VP failed to have any 
effect on the primary outcome measure of myocardial infarction. Interestingly our 
data revealed no change in haemodynamic parameters between GLP-1 treated and 
control experiments.
The major end point of the in vivo study was myocardial infarction in the risk zone as 
measured using TTC staining. In this regard, there was no statistically significant 
difference between the control group and those given just VP, suggesting that VP has 
no effect on myocardial ischaemic-reperfusion injury in this setting. Importantly, the 
GLP-1 treated group, which also received VP to prevent rapid enzymatic breakdown 
of GLP-1 by DPPIV, showed a statistically significant reduction in myocardial 
infarction as compared to both the control and VP groups. Fig 3.3
Our original hypothesis was that GLP-1, as a potent incretin, could induce 
myocardial protection against ischaemic-reperfusion injury by producing increased 
plasma insulin levels. Insulin has been shown to be protective in an in vivo rat model 
of myocardial injury (Jonassen et al. 2000). Although GLP-1 was strongly protective 
against ischaemic-reperfusion injury this appears to be unrelated to the serum insulin 
levels in our experiments. As can be seen in table 3.4 insulin levels in all the in vivo 
experiments showed wide variability not only between experiments but also within 
each individual experiment with values for measured insulin ranging from 83 pmol/1 
to 7194 pmol/1. This may be due to a number of reasons. Handling and induction and 
maintenance of anaesthesia both induce a stress response, which is variable between 
each experiment. Stress will lead to sympathetic activity, which will alter insulin 
homeostasis. Therefore, our experimental model may be unstable in terms of the 
insulin levels due to a variable stress response. Apart from the model-induced 
variability the method of insulin assay may be an additional cause of variability. The
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blood samples were taken fresh and spun at 4°C 6,000 rpm for 10 minutes with a 
buffer solution. The resulting plasma was then stored at -20° C. The samples were 
sent by courier on dry ice to Novo Nordisk, Bagsvaerd, Denmark from The Hatter 
Institute, London to be batch processed. It is possible that the samples were defrosted 
during transit leading to degradation of insulin, altering our results.
Blood glucose levels were measured at regular intervals throughout the experimental 
protocol and showed no statistically significant difference between the groups at any 
of the time points used for measurements. However, nearly all experiments showed a 
reduction in blood glucose when comparing the starting blood glucose level to the 
terminal blood glucose level. An analysis of the reduction in blood glucose levels 
showed statistical significance in the GLP-1 treated group as compared to both the 
control and VP group Figure 3.3. VP inhibits the breakdown of GLP-1 by DPPIV, 
prolonging the bioavailability and half-life of circulating, intact and hence active 
GLP-1. However, again the VP treated group as with the infarct data showed no 
difference from the control experiments in regard to glucose levels. The consistency 
in the blood glucose levels is at odds with our insulin data and would support the 
suggestion that the insulin sample collection method or assay were the source of 
variability rather than the model itself.
Although a rise in insulin and decrease in glucose is possible it must be remembered 
that these studies were undertaken in non diabetic animals which although not fasted, 
were not post prandial, suggesting any GLP-1 mediated stimulation of insulin release 
is likely to be small, because the insulinotropic effects of GLP-1 are glucose 
dependent.
GLP-1 receptors have been identified in the myocardium. Isolated cardiomyocytes 
studies have demonstrated an increase in c-AMP levels with no chronotropic or 
lusitropic effects (Vila Petroff et al, 2001). Our in vivo study demonstrated that GLP- 
1, at a dose of 4.8 pmolkg'1min'1, has no haemodynamic effects Table 3.2.
GLP-1 has been shown to increase blood pressure and heart rate in rats (Barragan et 
al. 1994). This difference may be due to the different dose of GLP-1 used and method
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of delivery. A study using a similar dose of GLP-1 in a porcine model failed to note 
any change in blood pressure or heart rate (Deacon et al. 1996). In our in vivo 
experiments the degree of anaesthesia required to produce a stable open-chest 
experimental model, which causes myocardial depression, must also be taken into 
account. GLP-1 has been shown to have effects on the central control of blood 
pressure and pulse (Barragan et al. 1999).
In summary GLP-1 in vivo produced significant reduction in myocardial ischaemic- 
reperfusion injury as measured by histological infarct staining, without any effect on 
heart rate or blood pressure.
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Chapter 4 Glucagon-Like Peptide-1 In Vitro
4.1 Introduction
The in vivo experiments described in chapter 3 show that GLP-l administration in a 
open-chest rat model is associated with a significant protection against myocardial 
ischaemic-reperfusion injury. This protection may be attributed to GLP-1’s potent 
incretin actions, such as an insulinotropic effect on the pancreas and possibly an 
increased sensitivity to insulin in the tissues. Insulin has been shown to be protective 
in an experimental model of ischaemic-reperfusion injury in an isolated rat heart 
(Jonassen et al. 2001). In the clinical setting there remains intense debate, with some 
studies demonstrating protection against ischaemia (Krljanac et al. 2005) while others 
failing to show any benefit as part of GIK infusions against myocardial injury (Mehta 
at al. 2005). The initial hypothesis driving these clinical studies was not based on the 
anti-apoptotic actions or activation of the RISK pathway but on the presumed 
metabolic effects of insulin as part of a metabolic cocktail. More recent evidence has 
shifted the focus away from the metabolic cocktail to the individual actions of insulin 
as a pro-survival agent activating the RISK pathway (Sack et al. 2003) with a possible 
reduction in apoptosis (Zhang et al 2005).
An alternative hypothesis, for our study, was that the protection seen against 
myocardial ischaemia-reperfusion injury may have been a direct effect of GLP-1 on 
the myocardium, possibly transduced by the recently identified GLP-1 receptor in the 
heart rather than its actions as an incretin. To isolate the mode of action of GLP-1 it 
was necessary to perform experiments in a setting where insulin could, in effect, be 
excluded from the model. To do this it is necessary to establish an in vitro model of 
myocardial ischaemia where the myocardium is in effect isolated from circulating 
peptide mediators. This would allow GLP-1 to be used in the absence of circulating 
insulin, thereby clarifying whether insulin was required in the tissues for GLP-1 to be 
protective in myocardial ischaemic-reperfusion injury. In vitro experiments using 
isolated perfused (Langendorff) hearts, also allow the use of a controlled glucose 
level. The concentration of glucose in the perfusate used in the experiment is
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predetermined and therefore any effect of fluctuating glucose seen in the in vivo 
setting is avoided.
A great deal of experience in the use of isolated perfused (Langendorff) hearts has 
been accumulated at the Hatter Institute where these experiments were performed. 
The in vitro model of myocardial ischaemic-reperfusion injury has been thoroughly 
validated and used extensively to explore the mechanisms involved in the reperfusion 
injury salvage kinase (RISK) pathway.
4.2 Materials and Methods
Male adult Sprague-Dawley rats (350-450g) were used for these studies. See chapter 
2, Section 2.4 for a detailed description of methods and materials used.
GLP-1
GLP-1 0.3nmol was added to the buffer of treated hearts.
VP
VP (20mgl1) is stored as an anhydrous powder and added to buffer to provide a 
concentration of 20 mgl'1.
4.2.1 In Vitro Infarct Model in Rat Heart
The isolated crystalloid-perfused rat heart model of ischaemic-reperfusion was 
employed for this study to simulate the pathological condition of myocardial 
ischaemic-reperfusion injury for several reasons: (1) it is a highly reproducible robust 
preparation which permits the measurement of: contractile function, morphological 
markers (such as infarct size) and electrophysiological markers (such as arrhythmias); 
(2) it allows the study of large numbers in a relatively short period of time and 
provides reproducible data; (3) it allows the examination of various pharmacological 
agents in the setting of ischaemic reperfusion injury, (4) it removes the confounding 
effects of the systemic circulation (neuro-hormonal factors) and therefore allows one 
to examine the direct effect of interventions on the myocardium (Sutherland et al. 
2000).
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The disadvantages of this preparation include: (1) the heart being isolated from 
blood-borne factors and neuronal innervation; (2) the preparation is constantly 
deteriorating (Sutherland et al. 2000).
4.3 Parameters Recorded
4.3.1 Temperature
Temperature was continuously monitored by a thermo-probe inserted into right 
ventricle by an incision made at the base of the pulmonary artery, and was maintained 
between 37.0°C and 37.5°C. Temperature was controlled by the use of a 
thermostatically-controlled water-jacketed system in which all glass reservoirs and the 
heart perfusion chamber are surrounded by rapidly flowing warmed water at 37.0- 
37.5°C, using a water circulator.
4.3.2. Rate Pressure Product and Coronary Flow
A latex, fluid-filled, iso-volumic balloon was introduced into the left ventricle via the 
left atrium, through a hole made by removing the left atrial appendage, to monitor 
contractile function of the left ventricle (figure 4.1). The balloon was inflated with 
distilled water to give a left ventricular end diastolic pressure of 4-8 mmHg, which 
was displayed on the PowerLab monitor. Left ventricular developed systolic and 
diastolic pressures, heart rate and coronary flow were noted at regular intervals.
4.3.3 Infarct Size Evaluation
The risk zone and percentage infarction of the area at risk were measured as described 
in detail in chapter 2, section 2.4.8
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4.3.4 Biochemical Buffer Analysis
Samples of the buffer were tested at regular intervals to check the pH, oxygen and 
carbon dioxide content as well as the glucose levels within the perfusate.
4.3 Ischaemic protocols
Our primary goal was to repeat the experiments performed in vivo in an in vitro 
model, so in essence, the same protocols as used in the in vivo study were repeated in 
the in vitro study. The major difference was that the ischaemic period was increased 
from thirty minutes as used in the in vivo to thirty-five minutes in the vitro study 
based on the experience already gained whilst characterization experiments were 
performed and from the vast experience of the Hatter Institute. This experience had 
suggested that thirty five minutes of ischaemia would produce the most effective 
ischaemic insult whilst still allowing some myocardium to be salvageable at 
reperfusion. The reperfusion period of one hundred and twenty minutes was 
maintained for both in vitro and in vivo protocols. . At the end of reperfusion the 
hearts were subjected to Evans Blue demarcation of prior to TTC staining of the 
infracted tissue.
4.4 Statistical analysis
Statistical analysis was performed using Apple Macintosh iMac computers and the 
statistical package StatView Version 4.5. Data was expressed as means ± SEM. One 
way analysis of variance between group means was performed using an ANOVA 
factorial method.
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4.5 Results
4.5.1 Technical exclusions
A total of thirty seven animals were used in the in vitro experiments described in this 
chapter. Five animals were excluded for the following technical reasons, including 
poor left ventricular developed pressure during stabilisation, aortic wall damage at the 
time of cannulation and persistent or recurrent ventricular fibrillation during 
ischaemia or reperfusion. Arrhythmias were a common occurrence during early 
reperfusion and were usually self-limiting or easily terminated.
4.5.2 Infarct size and risk size
There were no significant differences between the groups in regard to cardiac weight 
and risk volume (Table 4.1). The infarct to risk ratio in the control and VP treated 
groups was 60.5 ± 3 % and 52.5 ± 4 %  respectively. The GLP-1 and VP treated group 
achieved an infarct to risk ratio of 29.3 ± 3 % which was statistically significant 
p<0.0001 in comparison to the control and VP groups. This is demonstrated 
graphically in figure 4.1
4.5.3 Coronary flow and LV function
There were no statistically significant differences in heart rate or developed left 
ventricular pressure between the groups during stabilisation, ischaemia or reperfusion. 
The rate pressure product (RPP) for the groups is demonstrated in Table 4.2. 
Ischaemia produced a fall in both the coronary flow and RPP when compared to 
stabilisation. At reperfusion there were improvements in both parameters to values 
below that obtained during stabilisation followed by a time related decline in both 
parameters until termination of the experiment.
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Table 4.1 C haracteristics o f  A nim als in T reatm ent G roups
Groups Number Body 
Weight (g)
Heart 
Weight (g)
Risk volume 
(cm3)
1. Control 9 389±19 1.90±0.06 0.541±0.017
2 VP. 10 387±20 1.98±0.07 0.555±0.037
3. GLP-1 + VP 13 380±12 1.89±0.11 0.530±0.029
Values are means ± SEM. There was no significant statistical difference between the 
groups.
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Figure 4.1 In vitro myocardial infarct size expressed as a percentage of the risk zone
A= Control n =  9, B= Valine Pyrrolidide n= 10 , C=. Glucagon-like peptide-1 n=13. 
Results are presented as means ± SEM (* = /MhOOl vs. Control and VP)
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Table 4.2 Rate pressure product analysis of groups throughout the ischaemia-reperfusion 
protocol
Group Stabilisation Ischaemia
5min 30min
Reperfusion
15min 120 min
Control 27 533 12 340 19 037 21 528 16 320
N=9 ± 3356 ± 1763 ± 1549 ±2129 ±2329
Valine Pyrrolidide 26 450 13 967 18 655 20 365 16 589
JV=10 ±3674 ±2278 ± 1233 ± 1945 ± 1429
GLP-1 28 469 12 424 18 005 19 246 15 823
«= 13 ±3225 ±2362 ±2046 ± 1667 ± 1129
Values are means ± SEM. The rate pressure product analysis for the in vitro groups is 
mmHg • beat-1 • min.
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4.6 Discussion
This part of the study confirmed the direct protective effect of GLP-1, independent of 
its incretin actions, against myocardial ischaemic-reperfusion injury with statistically 
significant reduction in myocardial infarction in the GLP-1 treated group in 
comparison to the control group.
At the time these experiments were performed, no previously published studies had 
looked at the actions of GLP-1 on the isolated perfused heart. There had been a 
previously published study looking at the actions of GLP-1 on isolated 
cardiomyocytes where GLP-1 was used at the concentration of lOnmol/L (Vila Petroff 
et al. 2001) and other cellular studies had used GLP-1 at lOnmol/L (Hui et al. 2003). 
We chose to use an initial dose of 0.3nmol GLP-1 based very broadly on the 
concentration of GLP-1 used in the in vivo experiments. To achieve this we dissolved 
lpg of GLP-1 in each litre of buffer. In vivo we had given 4.8 pmol/kg/min as 
infusion intravenously. As we achieved significant protection with this first attempted 
dose we chose to move forward with the study to investigate the mechanisms of the 
protective effect seen. If time had allowed then a full dose response curve would have 
been performed, however, with the time limits of this was deferred.
The aim of this part of the study was to confirm the protective effect of GLP-1 against 
myocardial ischaemic-reperfusion injury in the isolated perfused heart. This would 
establish that the protective effect of GLP-1 on the myocardium must be mediated in 
the absence of circulating insulin. Our isolated perfused heart model of myocardial 
ischaemic-reperfusion injury is devoid of circulating blood borne factors and by 
allowing the model to stabilise for a period of 15 to 20 minutes any residual insulin in 
the myocardial tissue would be washed out and no longer biologically active.
These in vitro experiments confirmed that GLP-1 was able to provide protection 
against myocardial ischaemic-reperfusion injury in the absence of circulating insulin 
and with a glucose that was held constant. The glucose in our perfusate was found to 
remain constant at 10.8 mmol/1.
The in vitro findings were similar to the in vivo results reducing infarct to risk ratio by 
approximately 32% compared to control and 22% compared to the VP treated group 
Figure 4.6. The infarct to risk ratio in the control and VP treated groups was 60.5 ± 3
- 8 7 -
% and 52.5 ± 4 %  respectively. The GLP-1 and VP treated group achieved an infarct 
to risk ratio of 29.3 ± 3 % which was statistically significant pO.OOOl in comparison 
to the control and VP groups.
Interestingly GLP-1 appears to have no effect on myocardial function. There were no 
significant changes in the heart rate, developed pressure and hence the RPP. GLP-1 
was quite obviously protecting the myocardium from ischaemic injury when given 
prior to the index ischaemia without affecting cardiac contractility or inotropy. This 
was at odds with the findings of some of the research previously published looking at 
the haemodynamic effects of GLP-1 as discussed in chapter 3, section 3.10. The 
isolated perfused heart model produced results on myocardial function that were in 
keeping with our findings in the in vivo model. VP in isolation again failed to show 
any changes in myocardial function in comparison to control.
Some researchers had demonstrated a vasodilator action for GLP-1 in vascular 
endothelium. A recently published clinical paper demonstrated a significant 
improvement in endothelial dysfunction in diabetic patients but failed to show any 
endothelial action in normal subjects suggesting that this action may be mediated by 
an insulin sensitisation, that is increasing the sensitivity of the tissues to circulating 
insulin, as well as GLP-1 incretin actions. (Nystrom et al. 2004). In experimental 
studies a vasodilator action has quite clearly been shown in the pulmonary vasculature 
(Golpon at al. 2001). However, we failed to show any significant change in coronary 
flow which should reflect changes in endothelial function. Other parameters measured 
showed no statistical difference between the three groups again confirming our 
findings from the in vivo setup with GLP-1 having no significant effect on RPP, the in 
vitro surrogate for haemodynamic function, or coronary flow.
In summary, GLP-1 in vitro provides significant protection against myocardial 
ischaemia-reperfusion injury as measured by the degree of myocardial infarction. This 
is in the absence of circulating insulin, when given prior to the index ischaemia. This 
would support the hypothesis that GLP-1 was acting directly on GLP-1 receptors 
located on myocardial cells leading to activation of the RISK pathways.
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Chapter 5 Mechanisms of Cardioprotection in Vitro
5.1 Introduction
In the previous chapters we have demonstrated that GLP-1 was able to induce 
myocardial protection against ischaemic-reperfusion injury both in vivo and in vitro 
when given prior to the onset of ischaemia. In both models GLP-1 was continued 
throughout ischaemia and reperfusion until the termination of the experiments. In 
addition, the preceding in vitro studies described in chapter 4 showed that GLP-1 
produced significant protection against myocardial ischaemia-reperfusion injury in the 
absence of circulating insulin with the knowledge that any insulin present in the 
tissues would be washed out during the 15 minute period of stabilisation used in the 
model. We now moved from establishing whether GLP-1 can provide protection, to 
the mechanisms underlying this protection. We investigated the possible role of GLP- 
1 receptor activation as well as the prosurvival kinases PKA, PI3K/AKT, ERK 1/2 
MAPK and the possible downstream targets eNOS and BAD.
5.1.2 GLP-1 Receptor inhibition
The aim of this part of the study was to determine whether GLP-1 induced myocardial 
protection is transduced by the GLP-1 cell surface receptor.
The existence of a myocardial GLP-1 receptor (Bullock et al. 1996) provided the first 
focus for further investigation. The GLP-1 receptor has been investigated thoroughly 
by other groups and specific agonists and antagonists identified. Exendin (9-39) is a 
potent GLP-1 receptor antagonist whilst exendin-4 (Macdonald et al. 2003) is a 
receptor agonist. Exendin (9-39) has also been described as an antagonist of the 
putative exendin receptor. This peptide blocks the stimulatory action of GLP-1 and of 
exendin-4, a GLP-1 receptor agonist, on cAMP production in the pancreatic acini. We 
investigated the role of the myocardial GLP-1 receptor in transducing the protective 
effects of GLP-1 on myocardial ischaemic-reperfusion injury. By antagonising the
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GLP-1 receptor with exendin (9-39) if GLP-1 still provided protection against 
myocardial ischaemic-reperfusion injury we would be able to surmise that the action 
of GLP-1 in attenuating ischaemic-reperfusion injury was independent of the specific 
GLP-1 receptor.
To isolate whether GLP-1 induced myocardial protection was transduced through the 
cell surface GLP-1 R we used the specific GLP-1 R, antagonist Exendin (9-39). The 
lizard Heloderma species, including H. horridum and H. suspectum are native to 
several American states and are poisonous. Lizard venom contains a number of highly 
bioactive peptides including the peptides exendin-3 and exendin-4. These peptides 
were named exendin (Eng et al. 1992 and Raufman et al. 1992) in that they were 
isolated from an exocrine gland and were subsequently shown to have endocrine 
actions. Although exendin-4 was originally found to stimulate amylase secretion from 
pancreatic acinar cells, subsequent experiments demonstrated that exendin-4 was a 
potent agonist for the mammalian GLP-1 receptor. Exendin-4 is much more potent 
than native GLP-1, largely due to its resistance to DPP-IV mediated inactivation. In 
contrast to GLP-1 which contains an alanine at position 2, exendin-4 has a position 2 
glycine, hence it is not a substrate for DPP-IV and has a much longer half life in vivo. 
A truncated version of exendin-4, exendin (9-39) binds to but does not activate the 
GLP-1 receptor, and functions as a GLP-1 receptor antagonist.
5.1.3 GLP 1 and PKA inhibition
GLP-1 acts in several tissues via the GLP-1 R leading to intracellular calcium influx 
and increased production of c-AMP which in turn leads to the c-AMP dependent 
activation of Protein Kinase A (PKA). This is thought to be one of the key signal 
cascades by which GLP-1 acts in cardiac tissues (Vila Petroff et al. 2001). On the 
other hand PKA has been demonstrated to play a role in protecting the ischaemic 
reperfused myocardium (Inserte et al. 2004). Therefore, we thought it would be 
interesting to investigate the involvement of this cell signaling pathway in GLP-1 
mediated myocardial protection by blocking the activation of PKA. To achieve this 
we used a cell permeable inhibitor of PKA, named Rp-cAMP (Adenosine 3’,5’-cyclic
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Monophosphorothioate, Rp-isomer, Triethylammonium salt) which is resistant to 
hydrolysis by phosphodiesterases which are responsible for the degradation and 
clearance of cAMP (Yokozaki et al. 1992 and Kaji et al. 1992). Rp-cAMP is a 
permeable cyclic adenosine monophosphate (cAMP) isomer which inhibits c-AMP 
dependent PKA.
Figure 5.1 Chemical structure of Rp-cAMP
5.1.4 GLP-1 and PI3Kinase Inhibition
Phosphatidyl inositol 3-OH kinase (PI3K) is central to the control of cell growth, 
proliferation and survival (Wymann et al. 2003). GLP-1 has been shown to activate 
PI3K in insulin secreting cells (Hui et al. 2003. PI3K is thought to be intimately 
involved in the transduction of anti apoptotic cell signals. Myocardial IPC has also 
been shown to involve activation of PI3K (Mocanu et al. 2002). We aimed to identify
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whether GLP-1 mediated myocardial protection was blocked by inhibition of this 
known pro-survival pathway using the PI3K inhibitor, LY-294002 or 
2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one. LY-294002 is a reversible, cell- 
permeable, potent, and specific P13K inhibitor (IC50 = 1.4 pM) that acts on the ATP- 
binding site of the enzyme. It also inhibits non-homologous DNA end-joining (NHEJ) 
in the 460 kDa phosphatidylinositol 3-like kinase DNA-PKcs, which is the catalytic 
subunit of DNA-activated protein kinase. LY 294002 does not affect the activity of 
EGF receptor kinase, MAP kinase, PKC, PI 4-kinase, S6 kinase even at 50 pM.
5.1.5 GLP-1 and ERK 1/2 MAPK Inhibition
Mitogen activated protein kinases (MAPK) are thought to play a vital role in the 
cellular adaptation to various stressful stimuli (Bogoyevitch et al. 1996) and there is 
mounting evidence that MAPKs are activated following ischaemic-reperfusion injury 
(Knight et al. 1996). To inhibit the ERK 1/2 MAPK we used the potent and selective 
non competitive inhibitor of ERK 1/2, U0126 (Favata et al. 1998) or l,4-Diamino-2,3- 
dicyano-1,4-bis[2-aminophenylthio]butadiene.
NHz
CN
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Figure 5.2 Molecular structure of U0126.
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5.1.7 GLP-1 and p70s6Kinase Inhibition
PI3K activation has been shown to lead to the activation of downstream p70s6K 
which phosphorylates members of the initiation complex of protein translational 
machinery. The p70s6K pathway is thought to regulate translational protein synthesis 
and is central in mammalian cellular growth and cell survival (Harada et al. 2001). 
We inhibited this pathway using rapamycin, a specific and potent inhibitor of mTOR, 
the upstream activator of p70s6K.
Rapamycin (its name is derived from the native word for Easter Island, Rapi Nui) is a 
triene macrolide antibiotic, which demonstrates anti-fungal, anti-inflammatory, anti­
tumour and immunosuppressive properties. Rapamycin has been shown to block T- 
cell activation and proliferation, as well as, the activation of p70s6K kinase and 
exhibits strong binding to FK-506 binding proteins. It also inhibits the activity of 
mTOR, (mammalian target of rapamycin) which functions in a signaling pathway to 
promote tumour growth. Rapamycin binds to a receptor protein (FKBP12) and the 
rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR 
with target proteins in this signaling pathway.
5.2 Materials and Methods
Male adult Sprague-Dawley rats (350-450g) were used for these studies. See chapter 
2, Section 2.4.5 for a detailed description of methods and materials used. When 
necessary, reagents were dissolved in dimethyl sulphoxide DMSO, (Sigma-Aldrich). 
Final solutions were no greater than 0.01% DMSO a concentration which has 
previously been shown to have no effect on cardiac function or infarct size in this 
model (Mocanu et al. 2000) and control solutions contained the same were 
appropriate. Exendin (9-39) 3nmol/L from Bachem (Merseyside UK), LY294002 
15pmol/L, U0126 lOpmol/L and Rapamycin 0.5nmol/ L were obtained from Tocris 
(Bristol, UK), Rp-cAMP 1.5pmol/L from Calbiochem (Nottingham, UK),
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5.2.1 In Vitro Infarct Model in Rat Heart
For a detailed description see chapter 2, section 2.4.8 and chapter 4 section 4.2.1 to
4.3. This model allowed us to explore the mechanisms of the GLP-1 protection 
against myocardial infarction, using specific agonists and antagonists.
5.2.2 Ischaemic protocols
All experiments were subject to the same period of index ischaemia that is 35 minutes 
of regional ischaemia as described in chapter 4 section 4.3, followed by 120 minutes 
of reperfusion.
5.2.3 Western Blotting
For a detailed description of the materials and methods used to perform Western blots 
please see Chapter 2, Section 2.5
5.2.4 Quantification of Protein Bands
The developed films were scanned on a flat-bed picture/document scanner, and the 
digital image was assessed using the National Institutes of Health (NIH) Shareware 
program, NIH Image (version 1.63). The relative densitometry for individual protein 
bands was determined by the grey scale technique, using the supplied program ‘Gel 
plotting macro’. The values were corrected if required for equal protein loading as 
determined by probing for p-actin.. Figure 5.3
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Figure 5.3 Western Blot p Actin
Legend
Equal Protein loading was confirmed by blotting for p Actin. This is an example blot taken 
for pActin
5.2.5 Western Blot Sample Collection
The phosphorylation status of various proteins, known to be integral components of 
proven prosurvival pathways, were examined. The proteins examined included 
phospho-BAD (Ser 136), phospho-BAD (Ser 112), p70s6K(Thr389) and phospho- 
p70S6 kinase (Thr421/Ser424), Akt (Ser 473), eNOS and ERK 1/2. Ischaemic 
preconditioning was used as a positive control in a number of the blots.
Treated hearts were stabilised for 10 minutes followed by 5 min of drug 
administration with GLP-1 (0.3nmol) and VP (20mg/l). A further set of experiments 
were performed with hearts exposed to GLP-1 for 10 minutes. Control experiments 
were performed as well ischaemic preconditioning experiments as a positive control 
in a number of Western blots.
5.2.6 Statistical Analysis
Statistical analysis was performed using Apple Macintosh iMac computers and the 
statistical package StatView Version 4.5. Data was expressed as means ± SEM. One 
way analysis of variance between group means was performed using an ANOVA
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factorial method. P values of less than 0.05 were taken to show statistical 
significance.
5.3 Results
5.3.1 Technical exclusions
A total of 82 animals were used in the in vitro experiments described in this chapter. 
Four experiments were excluded for technical reasons; including poor left ventricular 
developed pressure during stabilisation, aortic wall damage at the time of cannulation 
and persistent or recurrent ventricular fibrillation during ischaemia or reperfusion.
5.3.2 Risk Volume and Weight
There were no significant differences between the groups in regard to cardiac weight 
and risk volume (Table 5.1 results expressed as mean with SEM).
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Table 5.1 Characteristics of Animals in Treatment Groups
Groups Number Body 
Weight (g)
Heart Weight 
(g)
Risk volume 
(cm3)
Exendin(9-39)
+GLP-1
6 389±19 1.90±0.06 0 .411±0.017
Exendin Control 6 387±20 1.98±0.07 0.555±0.037
Rp-cAMP+ GLP-1 6 380±12 1.89±0.11 0.490±0.029
Rp-cAMP Control 6 396±12 1.94±0.3 0 .411±0.014
Control 6 406±18 1.98±0.5 0.4860±0.03
LY294002+GLP-1 6 410±12 1.90±0.4 0.474±0.013
LY 294002 Control 6 404±12 1.92±0.3 0.515±0.015
Rapamycin+ GLP-1 6 398±12 1.97±0.4 0.496±0.019
Rapamycin Control 6 402±12 1.93±0.2 0.479±0.016
All values are presented as means ± SEM
- 9 7 -
5.3.3 Infarct size and GLP-1 receptor inhibition
Exendin (9-39), a well known inhibitor of the GLP-1 receptor abolished the GLP-1 
mediated myocardial protection (57.3 ± 3.8 % vs. 26.7 ± 2.7% P <0.001).There was 
no significant difference between Control and GLP-1 with Exendin(9-39).Figure 5.4
5.3.4 Infarct size and PKA inhibition
In our experiments (Fig.5.5) when the PKA inhibitor Rp-cAMP was administered in 
vitro concomitantly with GLP-1+VP and throughout the experiments, it abolished the 
protection seen with GLP-1 alone. (57.5 ± 5.0% vs. 26.7 ± 2.7% P < 0.001). There 
was no significant difference between Control and GLP-1 with PKA.
5.3.5 Infarct size and inhibitors of the pro-survival pathways
In our studies, the protection that we observed was also abolished by the PI3K 
inhibitor LY294002 (43.4 ± 3.9% vs. 26.7 ± 2.7% P < 0.05) and by the ERK 1/2 
MAPK inhibitor U0126 (48.3 ± 8.6% % P < 0.01). The p70s6K inhibitor rapamycin 
also abolished protection (57.1 ± 4.9% vs. 26.7 ± 2.7% P < 0.05). Neither of these 
antagonists or inhibitors when given alone had any effect upon infarct size. Figure 5.5 
and Figure 5.6 There was no significant difference between Control and GLP-1 with 
these inhibitors.
5.3.6 Coronary Flow and Rate Pressure Product
There were no statistically significant differences in heart rate or developed left 
ventricular pressure between the groups during stabilisation, ischaemia or reperfusion. 
The coronary flow rate (ml min'1) and rate pressure product (RPP) is demonstrated in 
Figure 5.7 Ischaemia produced a fall in both the coronary flow and RPP when 
compared to stabilisation. At reperfusion there were improvements in both parameters
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to values below that obtained during stabilisation followed by a time related decline in 
both parameters until termination of the experiment
Figure 5.4 GLP-1 and the GLP-1 Receptor Inhibitor
B
Legend
In vitro myocardial infarct size expressed as a percentage of the risk zone. A= Control 
n= 6, B= VP n=10, C=. GLP-1 n=13, D= Exendin(9-39) and GLP-1 n=6. Results 
are presented as means ± SEM (* = PO.OOOl vs control)
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Figure 5.5 GLP-1 and Inhibitors of Pro-survival kinases Rp-cAMP and LY 294002
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Legend
In vitro myocardial infarct size expressed as a percentage of the risk zone. A=Control, 
B=GLP-1, C= GLP-1 and Rp-cAMP n= 6, D= Rp-cAMP control n=6, E= LY 
294002 and GLP-1 n=6, F= LY 294002 control n=6, Results are presented as means 
± SEM (* = P<0.0001 vs control)
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Figure 5.6 GLP-1 and Inhibitors of Pro-survival kinases U0 126 and Rapamycin
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Legend
In vitro myocardial infarct size expressed as a percentage of the risk zone. A = 
Control, B = GLP-1, C= U0126 and GLP-1 n=6, D=U0126 control n=6, E= 
Rapamycin and GLP-1 n=6,F= Rapamycin control n=6. Results are presented as 
means ± SEM (* = PO.OOOl vs control)
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Figure 5.7 Coronary Flow and Rate Pressure Product
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5.4 Western Blot Results
5.4.1 Technical exclusions
A total of 18 adult male Sprague-Dawley rats were used for the Western blot 
experiments described in this chapter. Two experiments were excluded for the 
following technical reasons, including aortic wall damage at the time of cannulation 
and persistent or recurrent ventricular fibrillation during ischaemia or reperfusion.
5.4.2 Akt
With Control or GLP-1 treated hearts there was no detectable bands for Akt 
phosphorylation. With IPC hearts significant Akt phosphorylation was detected. 
Figure 5.8
5.4.3 eNOs
There was no significant difference in the phosphorylation state of eNOS between 
control and treated hearts. Data not included.
5.4.4 ERK 1/2 MAPK
Again there was no significant difference in the phosphorylation state of ERK 1/2 
between control and treated hearts. Data not included.
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5.4.5 BAD (Ser 136)
We found no significant difference in the content of total BAD between control and 
GLP-1 treated hearts, whereas chemiluminescence demonstrated the presence of 
phospho-BAD (Ser 136) in GLP-1 treated hearts compared with control hearts. Figure 
5.9
5.4.6 BAD (Ser 112)
We found no significant difference in the content of total BAD between control and 
GLP-1 treated hearts or the presence of phospho-BAD (Ser 112) on 
chemiluminescence.
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Figure 5.8 Western Blots of Akt Phosphorylation.
Akt(Ser 473) phosphorylation
4 — Control—► <4— IPC —► GLP-1—►
1000 i
800 -
Relative 600 —
Density
(a.u)
400 -
200 -
0 - 1
Control IPC GLP-1
Legend
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Representative Western blots and relative densitometry demonstrating that Control and GLP- 
1 treated hearts had no detectable Akt bands whilst IPC produced significant phosphorylation. 
N=3 per for control and IPC, n=6 for GLP-1. The relative density shown below in the bar 
graphs.
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BAD 136
Figure 5.9 W estern blot show ing total BAD and phospho-BA D
Contro I GLP-1
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200  -
0 -
Control GLP-1
Legend
This is a single western blot showing Phospho-BAD (Ser 136) in control and isolated 
hearts (n=3 each) The band size is 28 kDA for phospho-BAD. The relative density 
shown below in the bar graphs.
- 107 -
5. Discussion
5.5.1 Infarct Studies
The in vitro infarction studies demonstrate clearly that GLP-1, is able to protect the 
myocardium from ischaemic-reperfusion injury when accompanied by an inhibitor of 
DPPIV namely VP, which appears to confer no benefit by itself. Our data show that 
the protective action of GLP-1 would seem to be conducted through activation of the 
GLP-1 R, demonstrated by the fact that exendin (9-39) appears to completely inhibit 
the action of GLP-1 on myocardial preservation This affirms its role as signal 
transducer for GLP-1 induced cardioprotection.
The GLP-1 R is a G protein coupled receptor, and a distinct member of the glucagon- 
secretin receptor super family that has been shown to function by causing intracellular 
calcium influx in addition to up-regulating cyclic-adenosine monophosphate (c- 
AMP).
The cAMP inhibitor Rp-cAMP abolished GLP-1 mediated protection in our 
experiments, suggesting that this component of the GLP-1 signal cascade is 
implicated in myocardial protection. Elevated levels of c-AMP have previously been 
thought to be detrimental in ischaemic myocytes. However it is likely that the amount 
of c-AMP produced may play a significant role in determining divergent signal 
pathways (Vila Petroff et al. 2001). Compartmentalization of G-protein coupled 
signalling has been the subject of numerous recent reports (Bers at al. 2001) and it is 
increasingly recognised that spatiotemporal regulation of PKA activity involves 
regulation of discrete c-AMP pools. The amount of cAMP produced may play a role 
in determining divergent signalling pathways that lead to antiapoptotic pathways. The 
cAMP produced is thought to be locked in particular micro domains, known as 
compartmentalization, which restrict its actions.
Myocardial protection by GLP-1 is abolished by the PI3K inhibitor LY294002 and by 
the p44/42 MAPK inhibitor U0 126 implicating both these well demonstrated 
prosurvival pathways in the cardioprotection mediated by GLP-1.
Each of these pathways appears to be essential for the protection afforded by GLP-1, 
as inhibiting them individually abrogates the entire protection, suggesting that they 
may act in parallel. We were unable to identify any significant difference between the
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inhibitors when individually added to GLP-1 treated hearts, with protection appearing 
to be an all or none phenomenon.
The p70s6K inhibitor rapamycin abolished GLP-1 mediated cardioprotection. 
Activation of the p70s6K may mediate IPC-induced protection via an anti-apoptotic 
mechanism, in which it phosphorylates and inactivates the pro-apoptotic protein BAD 
(Majewski et al.1999). In this regard, Jonassen and colleagues have demonstrated that 
the protection induced by insulin at the time of reperfusion is mediated by activation 
of the Akt-p70s6K-BAD pathway (Jonassen et al. 2001). Studies in haematopoietic 
cells, have also observed the requirement for both kinases cascades to be activated to 
induce cellular protection (Shelton et al. 2003).
The findings of these experiments can be summarised as follows:
1) GLP-1 mediated protection is transduced by the GLP-1 Receptor
2) This protection appears to involve several previously described constituents of the 
RISK pathway namely PI3K, ERK 1/2 and p70s6K, as well as c-AMP which has not 
previously been considered as a beneficial cell signal within the ischaemic 
myocardium.
5.5.2 Western blot data
From our infarct data we would have expected to find positive Western blot results for 
the RISK kinases implicated by the inhibition of myocardial protection by their 
specific blockers. For example, GLP-1 mediated myocardial protection is blocked by 
the ERK 1/2 MAPK kinase inhibitor U0 126, so we hoped to find a positive Western 
blot for ERK 1/2 in GLP-1 treated hearts. However, for all the RISK kinases we failed 
to find a positive Western blot result for GLP-1 treated hearts. In other words there 
were no significant differences between the levels of phosphorylated AKT, ERK 1/2, 
PKA or p70s6K between control and treated hearts with or without inhibitors.
This may be a result of the time point at which hearts were harvested for sampling. 
The transitory moment of the kinase activation by GLP-1 may have been missed. This 
is supported by other investigators research showing that GLP-1 induces a time- 
related phosphorylation of ERK 1/2 MAPK fractions in rat hepatocytes after two and
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five minutes exposure to GLP-1 which is not detectable after 10 minutes (Redonado et 
al. 2003). In the protocol we used, hearts were harvested after five minutes exposure 
to GLP-1 and further experiments were performed with ten minutes exposure to GLP- 
1. A major limitation of our study was the failure to use additional time points for this 
investigation which would have addressed this question.
The IPC experiments, used as a positive control, showed Akt and ERK 1/2 
phosphorylation, proving that our antibodies and methodology for performing 
Western blots was effective and used correctly.
We hypothesised from our findings and the observations of Redonados group, that the 
phosphorylation of the prosurvival kinases, even though short lived and difficult to 
assess, may have activated persistent downstream protective mechanisms which 
would explain the increased pancreatic cell survival seen in the literature and our own 
experience in the myocardium. We turned our attention to two such downstream 
targets, namely, eNOS and BAD and found interesting results concerning the latter. 
Bad is a proapoptotic member of the Bcl-2 family that can displace Bax from binding 
to Bcl-2 and Bcl-xL, resulting in cell death. Survival stimuli can lead to the inhibition 
of the apoptotic activity of Bad by activating intracellular signal pathways that lead to 
the phosphorylation of Bad. There are a number of phosphorylation sites on Bad and 
interestingly PKA, Akt or ERK 1/2 MAPK can phosphorylate these sites. The result is 
the binding of Bad to 14-3-3 proteins preventing Bad from binding to Bcl-2 and Bcl- 
xL and promoting cell death. Akt has been shown to promote cell survival via its 
ability to phosphorylate Bad at Ser 136 (She et al. 2005). Ser 112 has been shown to 
be the substrate in vivo and in vitro of p90RSK and mitochondria-anchored PKA 
(Bonni et al. 1998 and Harada et al. 1999). The extracellular signal regulated kinases 
ERK 1/2 are thought to act as a catalyst for the phosphorylation of p90RSK (Seger 
and Krebs 1995). Our Western blots demonstrated phosphorylation of Bad at Ser 136 
with no evidence of phosphorylation at Ser 112. Moreover, we were not happy with 
the quality of the phospho-Bad antibodies and more investigations are needed with 
respect of GLP-1 inducing Bad inactivation. However, the finding that GLP-1 results 
in the phosphorylation (hence inactivation) of Bad at least at Ser 136 gave us an 
insight into the possible end effectors responsible for GLP-1 mediated protection 
against cell death in the myocardial ischaemia-reperfusion injury.
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Using specific inhibitors we have been able to demonstrate that GLP-1 induced 
myocardial protection involves multiple pathways, which may induce in the end the 
inactivation of important antiapoptotic factors as Bad.
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Chapter 6 GLP-1 administered either before ischaemia or at 
reperfusion
Introduction
We have established that GLP-1 is able to protect the myocardium in both the in vivo 
and in vitro rat model against ischaemic-reperfusion injury when given throughout the 
experimental protocol. This effect is probably mediated by activation of the 
reperfusion injury salvage kinases (RISK) (Hausenloy and Yellon 2004) as suggested 
by the results of our experiments with blockade of specific known constituents of the 
RISK pathway. The activation of these pathways has been demonstrated to play a role 
in preconditioning as well as in reducing reperfusion injury. Therefore, we tested the 
hypothesis that GLP-1 can activate these prosurvival pathways when given prior to 
ischaemia or at reperfusion.
6.1 GLP-1 at Reperfusion
To salvage the ischaemic myocardium from infarction requires reperfusion. 
Reperfusion is therefore a prerequisite for cell survival, however, it is associated a 
cascade of deleterious effects, such as the generation of free radicals or oxidative 
stress and abrupt metabolic changes, known as reperfusion injury (Yellon 2003) 
Indeed some studies investigating reperfusion injury have demonstrated cellular injury 
in the absence of ischaemia. (Vanden Hoek et al 1996). In all our experiments to date 
GLP-1 had been given during stabilisation of the model prior to any ischaemic insult 
and continued throughout both ischaemia and reperfusion until the hearts were 
harvested for histological examination. We sought to clarify whether GLP-1 would 
induce myocardial protection when given after the index ischaemia but prior to 
reperfusion. In these experiments GLP-1 and VP were added to the perfusate and
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circulated through the apparatus ready to be delivered to the isolated perfused heart. 
Two sets of experiments were performed to investigate the role of GLP-1 at 
reperfusion. The first group R l, were performed with the GLP-1/VP treatment 
commenced 5 minutes prior to the end of the ischaemic period and continued for 15 
minutes into the reperfusion period, giving a total of 20 minutes treatment with GLP- 
1/ VP. For the rest of reperfusion period the hearts were switched back to plain buffer 
with no added GLP-1 or VP. A further set of experiments, Group R2, were performed 
with GLP-1/ VP commenced one minute prior to reperfusion and continued for 15 
minutes into reperfusion. Two groups were used based on the experience of previous 
investigators at the Hatter Institute. Figure 6.1
6.2 GLP-1 as a Preconditioning Mimetic
Ischaemic preconditioning is considered one of the most powerful forms of 
myocardial protection as discussed in chapter 1. We sought to identify whether GLP-1 
would act as a preconditioning mimetic. In these experiments classical ischaemic 
preconditioning experiments (two periods of 5 minutes global normothermic 
ischaemia interspaced with 10 minutes reperfusion before the 35 minutes lethal 
ischaemia and 120 minutes reperfusion) were compared to GLP-1 treated and control 
experiments. To test the hypothesis that GLP-1 could act as a pharmacological 
mimetic of classical ischaemic preconditioning, experiments were performed with 
GLP-1 given prior to index ischaemia for a period of 10 minutes followed by a 
washout period of 5 minutes prior to index ischaemia for 35 minutes followed by 120 
minutes reperfusion as in the rest of the experiments. Figure 6.2
6.3 Materials and Methods
Male adult Sprague-Dawley rats (350-450g) were used for these studies. See chapter 
2, Section 2.4.5 for a detailed description of methods and materials used.
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6.3.1 In Vitro Infarct Model in Rat Heart
For a detailed description see chapter 2, section 2.4.8 and chapter 4 section 4.2.1 to
4.3. This model allowed us to explore the mechanisms of the GLP-1 protection 
against myocardial infarction by altering the time point of exposure to GLP-1.
6.3.2 Statistical Analysis
Statistical analysis was performed using Apple Macintosh iMac computers and the 
statistical package StatView Version 4.5. Data was expressed as means ± SEM. One 
way analysis of variance between group means was performed using an ANOVA 
factorial method. P  values of less than 0.05 were taken to show statistical 
significance.
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Figure 6.1 Scheme o f  in vitro GLP-1 at reperfusion experimental protocols
Group 1 Control
Stabilisation 15 Ischaemia 35 min Reperfusion 120 min
Group R l GLP-1
Stabilisation 15 Ischaemia 35 min Reperfusion 120 min
j i i
GLP-1 0.3nmol /  VP 20mgr'
Group R2 GLP-1
Stabilisation 15 Ischaemia 35 min Reperfusion 120 min
GLP-1 0.3nmol / VP 20mgr'
Hearts in all groups are stabilised for a minimum o f  15-20 minutes. In Group R l, GLP-1 and 
VP were perfused through the hearts after 30 minutes o f  ischaemia., that is five minutes prior 
to the onset o f  reperfusion. In Group R2, GLP-1 and VP were perfused into the heart after 34  
minutes o f  ischaemia, that is one minute prior to reperfusion, and continued into reperfusion 
for a total o f  20 minutes respectively.
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Figure 6.2 Schematic o f  in vitro Ischaem ic preconditioning experimental protocols and GLP- 
1 as a preconditioning mimetic
IPC
Stab 5 10 5 10 Ischaemia 35 min Reperfusion 120 min
i i t i
Two 5 min periods of global ischaemia with 10 minutes intervening reperfusion
GLP-1 as a PC mimetic
Stab Ischaemia 35 min Reperfusion 120 min
GLP-1 0.3nmol and VP 20mg/l for 10 minutes followed by 5 mins washout
Hearts in all groups are stabilised for a minimum o f  15-20 minutes. IPC = Ischaemic 
preconditioning
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6.4 Results
6.4.1 Infarct size and GLP-1 given at reperfusion
In group Rl ,GLP-1 given at reperfusion also reduces the infarct in the risk zone to 
30.6 % +/- 3.4. (p<0.0001 vs. control). However in group R2 with GLP-1 given one 
minute prior to reperfusion there was an absence of protection against ischaemic 
reperfusion injury. Figure 6.3
6.4.2 Infarct size and GLP-1 as a preconditioning mimetic
Preconditioning reduced the infarction in the risk zone to 26.7 % +/- 2.1 compared to 
control 58.7 % +/- 3.5 (p<0.0001). GLP-1 given as a preconditioning mimetic reduced 
infarction in the risk zone to 29.8 % +/- 6.8. Figure 6.4
6.4.3 Coronary Flow and Rate Pressure Product
There were no statistically significant differences in heart rate or developed left 
ventricular pressure between the groups during stabilisation, ischaemia or reperfusion. 
Ischaemia produced a fall in both the coronary flow and RPP when compared to 
stabilisation. At reperfusion there were improvements in both parameters to values 
below that obtained during stabilisation followed by a time related decline in both 
parameters until termination of the experiment
6.4.4 Risk Volume and Weight
There were no significant differences between the groups in regard to cardiac weight 
and risk volume. Table 6.1
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Figure 6.3 GLP-1 at Reperfusion
B
Legend
In vitro myocardial infarct size expressed as a percentage of the risk zone. A= Control 
n= 6, B= GLP-1 /VP 5 minutes prior to reperfusion n=7, C=. GLP-1/VP 1 minute 
prior to reperfusion n=7. Results are presented as means ± SEM (* = PO.OOl vs 
control
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Figure 6.4 GLP-1 as a Preconditioning Mimetic
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Legend
In vito myocardial infarct size expressed as a percentage of the risk zone. A= Control 
n= 6, B= IPC Ischaemic Preconditioning n=6, C= GLP-1 as a preconditioning 
mimetic, n-4. Results are presented as means ± SEM (* = PO.OOOl vs control)
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Table 6.1 Characteristics of Animals in Treatment Groups
Groups Number Body 
Weight (g)
Heart Weight 
(g)
Risk volume 
(cm3)
GLP-1 Reperfusion 7 412±18 2.04±0.12 0.525±0.018
GLP-1 Reperfusion 
Control
7 402±16 1.98±0.10 0.496±0.019
GLP-1
Preconditioning
Mimetic
4 386±14 1.89±0.06 0.464±0.017
Ischaemic
Preconditioning
6 392±12 1.92±0.08 0.515±0.037
Control 6 406±18 1.94±0.08 0.4860±0.03
All values are presented as means ± SEM
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6.5 Discussion
Ischaemic preconditioning (IPC) has been clearly demonstrated to be strongly cardio­
protective by numerous of investigators across a variety of different animal models as 
well as in man as discussed in chapter 1. The RISK pathway is activated by IPC and a 
number of pharmacological agents (Hausenloy and Yellon 2004). The hypothesis that 
GLP-1 could mimic classical ischaemic preconditioning and provide protection 
against myocardial injury was tested by giving GLP-1 for a short period of 10 minutes 
immediately after stabilisation prior to any index ischaemia. GLP-1 given as a 
preconditioning mimetic protected against myocardial ischaemic-reperfusion injury 
with a significant decrease in myocardial infarction in comparison to control 
experiments. The degree of protection was not statistically different from the 
protection achieved by IPC or by giving GLP-1 throughout the index ischaemia and 
reperfusion or in comparison to giving GLP-1 five minutes prior to reperfusion.
Our results showed a surprising outcome when GLP-1 was given one minute prior to 
reperfusion when compared to the second set of experiments when GLP-1 was given 
five minutes prior to reperfusion. There was an absence of protection against 
myocardial injury in the group treated from one minute prior to reperfusion whilst the 
five minute group produced a similar degree of protection to our initial in vitro GLP-1 
treated experiments. This could be explained by GLP-1 failing to activate the 
reperfusion injury salvage kinase or RISK pathways in time. When given one minute 
prior to reperfusion GLP-1 may fail to result in the RISK pathway kinases activation 
prior to the deleterious effects of reperfusion as a result of not reaching the tissues in 
adequate concentrations just at the moment of reperfusion. This could in turn be a 
consequence of the experimental set up in the Langendorff apparatus. Attempts are 
made to achieve the least possible dead space in the tubing carrying the GLP-1 treated 
buffer so as to reach the heart as quickly as possible when the buffers are switched 
over. This theory is supported by the finding that the second group in which GLP-1 
was started five minutes prior to the onset of reperfusion is protected.
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In summary these experiments confirm that in an in vitro rat model GLP-1 protects 
the myocardium against ischaemic reperfusion injury when given five minutes prior to 
the onset of reperfusion or as a preconditioning mimetic.
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Chapter 7 Final considerations
7.1 Summary and Discussion
Myocardial infarction and coronary artery disease are amongst the most important and 
sadly prevalent pathologies dealt with by medical and surgical specialists in the 
healthcare field. Diabetes is considered one of the most important risk factors for the 
development of coronary artery disease. Indeed outcomes in terms of morbidity and 
mortality for those with diabetes and coronary artery disease are considerably worse 
in comparison to non diabetic individuals.
In this context the investigation of novel compounds such as GLP-1, with potential 
beneficial effects on the control and treatment of diabetes in relation to their possible 
actions in the myocardium, holds a great deal of interest. This thesis investigates the 
possibility that GLP-1 protects the myocardium against ischaemia-reperfusion injury 
and further seeks to identify the mechanisms by which this novel peptide hormone 
acts in relation to previously well described cell signal cascades, such as the RISK 
pathway.
GLP-1 possesses a number of properties, which makes it a potentially ideal anti­
diabetic agent (see chapter 1). Furthermore this peptide also possesses other properties 
which have the potential to exert a direct cardioprotective effect. In this regard GLP-1 
has also been shown to reduce pancreatic beta cell apoptosis (Urusova et al. 2004). 
Moreover the presence of the GLP-1 receptor (GLP-1 R) in the heart, and the 
evidence that GLP-1 promotes the activity of PI3K in beta cells (Hui et al. 2003), a 
kinase that has been clearly associated with myocardial protection in the setting of 
ischaemic reperfusion injury (Hausenloy et al. 2004) as well as preconditioning 
(Mocanu et al. 2002), allows one to hypothesise a novel and independent action of 
GLP-1 in the setting of ischaemia-reperfusion damage.
GLP-1 induces an increased level of cAMP in cardiomyocytes, which, in turn, 
activates Protein Kinase A (PKA) (Vila Petroff et al. 2001). GLP-1 has an anti 
apoptotic action on insulin secreting cells mediated by c-AMP, and PI3K. Activation
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of PI3 kinase leads to the phosphorylation and inactivation of the pro-apoptotic BAD 
by causing it to bind to 14-3-3 proteins (Zha et al. 1996). BAD is a proapoptotic 
member of the Bcl-2 family that can displace Bax from binding to Bcl-2 and Bcl-xl, 
resulting in cell death. Elevated levels of cAMP have previously been thought to be 
detrimental in ischemic cardiomyocytes. However, recent work in beta cells has 
shown that GLP-1 produced lower concentrations of cAMP compared to other cAMP 
increasing agents. The amount of cAMP produced may play a role in determining 
divergent signalling pathways that lead to antiapoptotic pathways. The cAMP 
produced may also be locked in particular micro domains, known as 
compartmentalization, which restrict its actions (Bers at al. 2001). GLP-1 mediated 
increases in cAMP (comparable to isoproterenol) failed to cause any inotropic or 
lusitropic effect (Vila Petroff et al. 2001), supporting the suggestion for such 
compartmentalization. Compartmentalization of G protein-coupled signalling has 
been the subject of numerous reports, and it is increasingly recognized that 
spatiotemporal regulation of PKA activity involves regulation of discrete cAMP 
pools.
GLP-1 has been shown to increase blood pressure and heart rate in rats (Barragan et 
al. 1996). In our study we failed to demonstrate any significant change in blood 
pressure or heart rate, both, in vivo and in vitro. This difference may be due to the 
different dose of GLP-1 used and method of delivery. A study using a similar dose of 
GLP-1 in a porcine model failed to note any change in blood pressure or heart rate 
(Deacon et al. 1996). In our in vivo experiments the degree of anaesthesia required to 
produce a stable open chest experimental model, which causes myocardial depression, 
must also be taken into account. GLP-1 has been shown to have effects on the central 
control of blood pressure and pulse (Barragan et al. 1999 and Isbil-Buyukcoskon et al.
2004). This central mechanism is excluded in the in vitro setting.
GLP-1 is a potent incretin, which could suggest a possible mechanism to explain our 
initial findings in the in vivo study. However, although a rise in insulin and decrease 
in glucose is possible, it must be remembered that these studies were undertaken in 
non diabetic animals which although not fasted, were not post-prandial, suggesting 
any GLP-1 mediated stimulation of insulin release is likely to be small, because the 
insulinotropic effects of GLP-1 are glucose dependent. Furthermore in our additional
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studies using the in vitro, isolated perfused heart rat heart, we obtained a similar 
degree of myocardial protection
The myocardial protection observed in this study is reproduced in both the in vivo and 
in vitro models; the latter being specifically relevant, as in this setting, there is an 
absence of circulating insulin. Any residual insulin in these hearts at the time of 
harvesting from the rats would be lost from the tissues during the stabilisation period 
on the Langendorff apparatus. Since insulin has been shown to be cardioprotective, 
activating PI3K and reducing post ischaemic myocardial apoptotic death (Baines et al. 
1999 and Jonassen et al. 2001), the ability of GLP-1 to protect against ischaemia 
reperfusion injury in this model demonstrates that it acts independently of its incretin 
properties.
Recombinant GLP-1 has been shown to prevent the accumulation of pyruvate and 
lactate in a porcine model of myocardial ischaemia, but failed to show any decrease in 
the infarction (Kavianipour et al. 2003). Species differences, methodology, the long 
duration of the ischaemic insult and the lack of an inhibitor of the rapid enzymatic 
degradation of GLP-1 may account for the abolition of myocardial protection.
Our results demonstrate that GLP 1 confers myocardial protection when administered 
together with an inhibitor of DPP-IV, valine pyrrolidide which, appears to confer no 
benefit by itself.
Exendin 9-39, a GLP 1 R antagonist, appears to completely inhibit the protective 
action of GLP-1 on myocardial preservation, confirming the role played by this 
receptor as a signal transducer for GLP-1 induced cardioprotection. The c-AMP 
inhibitor Rp-cAMP abolished protection, confirming this known GLP-1 pathway as a 
possible downstream mechanism. The protection was also abolished by the PI3K 
inhibitor LY294002, by the ERK 1/2 MAPK inhibitor U0 126 and by Rapamycin an 
inhibitor of p70s6K, implicating these well demonstrated pro-survival pathways in the 
cardioprotection mediated by GLP-1.
Recent studies have demonstrated a direct endothelial relaxant action for GLP-1 
(Golpon et al. 2001 and Nystrom et al. 2005). Our in vitro model showed no 
significant change in coronary artery flow. This does not exclude a vascular 
endothelial role for GLP-1 in the heart, as our experimental model -  the isolated
- 1 2 5 -
retroperfused Langendorff heart- is not the best model for assessing myocardial 
endothelial function.
We have shown, for the first time, that GLP-1 is able to protect the myocardium 
against ischaemia-reperfusion injury, not only in vivo, but also in vitro. GLP-1 
appears to protect via activation of its receptor and the downstream signalling 
prosurvival pathways PKA/cAMP, PI3K/Akt, ERK 1/2 MAPK. Amongst different 
targets of these pathways our data confirm p70s6K (as rapamycin inhibits GLP 1 
protection) and Bad (as Western blots confirm its phosphorylation and hence 
inactivation, in GLP 1 treated hearts). Figure 7.1
Each of these appears to be essential for the protection afforded by GLP-1, as 
inhibiting them individually, abrogates the protection, suggesting that they may act in 
parallel. However it is worth mentioning that inhibiting PI3K seems to only partially 
abrogate protection, a result which can be interpreted as due to a possible crosstalk 
between these pathways. More investigations in the area are needed.
7.2 Summary of findings
• GLP-1 acts to limit myocardial ischaemia-reperfusion injury in both a rat in 
vivo and in vitro model.
• GLP-1 appears to have no measurable haemodynamic actions in vivo or in 
vitro in our models.
• The protective effect of GLP-1 against myocardial cell death implicates the 
activation of the GLP-1 receptor and downstream signalling cascades 
cAMP/PKA, PI3K/Akt and ERK 1/2
• GLP-1 affords myocardial protection whether given prior to ischaemia or at 
the time of reperfusion
• GLP-1 results in the phosphorylation and hence deactivation of the pro- 
apoptotic factor BAD.
• GLP-1 can act as a preconditioning mimetic.
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7.3 Limitations
Our study investigated the influence of GLP-1 upon myocardial infarction as a 
measurable end point of ischaemic-reperfusion injury. Once a positive reduction in 
the degree of infarction was confirmed we proceeded to try and characterize the 
mechanisms by which GLP-1 achieved this protection.
We did not perform experiments in vivo where the glucose level was standardised or 
clamped. Our initial in vivo protocol involved the measurement of intact GLP-1 as 
well as its degradation products and DPPIV activity. However, due to circumstances 
beyond our control these samples have never been processed so this data is 
unavailable. It would have been interesting to investigate the effect of different 
glucose levels in the perfusate upon the GLP-1 protection in the in vitro settings. All 
our in vitro work was done using standardised glucose content.
GLP-1 is known to have anti-apoptotic actions in (3-cells in the pancreas. Myocardial 
infarction is known to be a composite of necrosis and apoptosis. Our experiments did 
not look at the contribution of apoptosis and necrosis in the resultant myocardial 
infarction and whether this was altered by GLP-1.
Our quest for the identification of a mechanism of action for GLP-1 examined 
components of the RISK pathway. Although we were able to inhibit GLP-1 mediated 
myocardial protection with inhibitors of the RISK pathway we failed to capture 
phosphorylation of these components in our Western blot experiments. This may be 
attributed to our protocol missing the time points at which GLP-1 phosphorylated 
these components, This is supported by other investigators research showing that 
GLP-1 induces a time-related phosphorylation of ERK 1/2 MAPK fractions in rat 
hepatocytes after two and five minutes exposure to GLP-1 which is not detectable 
after 10 minutes (Redonado et al. 2003). In the protocol we used hearts were 
harvested after five minutes exposure to GLP-1 and further experiments were 
performed with ten minutes exposure to GLP-1. A major limitation of our study was 
the failure to use additional time points for this investigation. The transitory moment 
of the kinase activation by GLP-1 may have been missed. Further experiments would 
be needed in order to try and tease out the time points of GLP-1 activity on these 
factors.
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We did, however, confirm the phosphorylation of BAD by GLP-1, however more 
investigations regarding other members of Bcl-2 family would have been ideally 
performed. Our investigations have been carried out in a normoglycaemia rat models, 
for validation these should be repeated in a diabetic model.
Figure 7.1 GLP-1 cell signalling in the ischaemic myocardium
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7.4 Clinical Implications
Our data brings a new insight into the possible therapeutic potential for this class of 
drugs currently undergoing trials in the treatment of non-insulin dependent diabetes.
7.5 Future Directions
Valine pyrrolidide is a prototype DPPIV inhibitor and GLP-1 analogues are stabilised 
forms of GLP-1 (optimised for once daily administration). It is interesting to observe 
that the cardioprotective effect of GLP-1 was not shared by DPPIV inhibition alone 
(VP had little or no effect). GLP-1 analogues and DPPIV inhibitors are both novel 
therapeutic approaches to the treatment of type 2 diabetes -  a condition characterised 
by increased risk of acute myocardial infarction. Our data suggests, therefore, that 
GLP-1 analogues may possess an additional benefit (i.e. cardioprotection) which is 
not shared by DPPIV inhibitors -  a property that may help distinguish between these 
newly emerging therapeutic approaches. Furthermore it may be of interest, therefore, 
to study the effects of stable GLP-1 analogues in future experiments.
A great deal of interest has been focused on the metabolic consequences of ischaemia 
in the myocardium and its modification with glucose, insulin and potassium (GIK) has 
reaped rewards (Sodi Polares 1962 and Opie 1970). The actions of GLP-1 on 
myocardial metabolism have yet to be fully elucidated.
It would be interesting to speculate whether the benefits reported in the clinical trials 
(such as the DIGAMI (Malmberg et al. 1995) and ECLA ( Diaz et al. 1998) and 
other trials (Doenst et al. 2003)), reporting benefits from the administration of GIK 
therapy at the time of reperfusion, following an acute myocardial infarction, were due 
to the activation of the reperfusion injury kinase pathway.
The CREATE-ECLA randomized controlled trial reported in 2005 (Mehta et al.
2005). In this large, international randomized trial, high-dose GIK infusion had a 
neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute 
STEMI. This study cast a shadow over the role of GIK in acute myocardial infarction.
- 129  -
The proponents of the GIK have pointed to the limitations of this study in over twenty 
thousand patients with acute myocardial infarction and suggest that the critical factor 
may be the timing of therapy which should ideally be initiated either prior to or at the 
time of reperfusion (Apstein at al. 2005).
Recent studies have shown that fluoroscopic-guided intramyocardial injection in the 
pig model is a feasible and safe procedure for targeting the delivery of therapeutic 
agents to the area of myocardium at risk from ischaemia-reperfusion injury (Gwon et 
al. 2001). Therefore the local delivery of therapeutic agents such as GLP-1 themselves 
or the adenoviral vectors (carrying mutated genes which over-express growth factors) 
may provide a potential method for targeting and up-regulating the RISK-pathway in 
the clinical setting of reperfusion. Alternatively for patients undergoing an anticipated 
episode of ischaemia-reperfusion injury, such as during CABG surgery or elective 
coronary angioplasty, gene transfer may be a possible method of delivering growth 
factors to myocardium at risk of lethal reperfusion-induced injury.
Further studies are required to verify and further investigate the action of GLP-1 and 
its metabolites on the myocardium.
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